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The blood-brain barrier (BBB) is a highly specialized brain endothelial structure of the fully differentiated
neurovascular system. In concert with pericytes, astrocytes, and microglia, the BBB separates components
of the circulating blood from neurons. Moreover, the BBB maintains the chemical composition of the neuronal
‘‘milieu,’’ which is required for proper functioning of neuronal circuits, synaptic transmission, synaptic
remodeling, angiogenesis, and neurogenesis in the adult brain. BBB breakdown, due to disruption of the tight
junctions, altered transport of molecules between blood and brain and brain and blood, aberrant angiogen-
esis, vessel regression, brain hypoperfusion, and inflammatory responses, may initiate and/or contribute to
a ‘‘vicious circle’’ of the disease process, resulting in progressive synaptic and neuronal dysfunction and loss
in disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple scle-
rosis, and others. These findings support developments of new therapeutic approaches for chronic neurode-
generative disorders directed at the BBB and other nonneuronal cells of the neurovascular unit.The great British physiologist Hugh Davson, one of the founders
of the modern concept of the blood-brain barrier (BBB), dis-
cussed in his state-of-the art review some 30 years ago the model
and functions of the BBB (Davson, 1976). In Davson’s era, and
later in the eighties and early nineties, very little, if anything,
was known about the role of the BBB in the pathogenesis of brain
disorders, a field that has exploded over the past decade, and is
the subject of the present review.
Introduction
At the beginning of the last century, Lewandowsky (1900) sug-
gested that the absence of central nervous system (CNS) phar-
macological actions of intravenously administered bile acids or
ferrocyanide was due to the BBB, a mechanical membrane
which separated blood from brain. The failure of the intrave-
nously administered dye, trypan blue, to stain the brain and spi-
nal cord tissue confirmed this view (Goldmann, 1909) (Figure 1A).
It was suggested that such a barrier did not exist between the
cerebrospinal fluid (CSF) and brain (Goldmann, 1913) (Figures
1B and 1C).
Electron microscopy (EM) studies with ferritin and horseradish
peroxidase have since shown that the BBB is localized at the
level of tight junctions (TJ) between adjacent brain endothelial
cells (BEC) (Reese and Karnovsky, 1967; Brightman and Reese,
1969). The molecular nature of different interendothelial junction
proteins, and their roles in mediating the BBB breakdown in
various CNS diseases, are discussed below.
Physiological studies in the fifties, sixties, and seventies began
to change the concept of the BBB as an impermeable barrier.
Owing to the presence of highly specialized and diverse trans-
port systems for chemically well-defined substrates (Ohtsuki
and Terasaki, 2007), early transport studies demonstrated that
the brain endothelium, a site of the BBB in vivo, regulated active
transport of ions (Davson, 1976) and carrier-mediated transport178 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.of glucose (Yudilevich and De Rose, 1971) and amino acids (AA)
(Oldendorf, 1973; Davson, 1976). The role of different BBB trans-
porters in the normal brain as potential therapeutic targets or ef-
fectors in the development of brain pathology is discussed later.
Today, we accept the view that the BBB limits the entry of
plasma components, red blood cells, and leukocytes into the
brain. If they cross the BBB due to an ischemic injury, intracere-
bral hemorrhage, trauma, neurodegenerative process, inflam-
mation, or vascular disorder, this typically generates neurotoxic
products that can compromise synaptic and neuronal functions
(Zlokovic, 2005; Hawkins and Davis, 2005; Abbott et al., 2006).
An intact BBB is also a major obstacle for the development of
drugs for CNS disorders. Approximately 98% of small molecule
drugs and all large molecule neurotherapeutics, e.g., recombi-
nant peptides, proteins, anti-sense-agents and genetic vectors,
are normally excluded from the brain (Pardridge, 2007). When
confronted with the BBB, they behave essentially like trypan
blue (Figure 1).
Neurovascular System
In humans, the brain receives up to 20% of cardiac output. If
cerebral blood flow (CBF) stops, brain functions stop in seconds
and damage to neurons may occur in minutes (Girouard and
Iadecola, 2006).
The normal neuronal-vascular relationship is critical for normal
brain functioning. It has been estimated that nearly every neuron
in human brain has its own capillary (Zlokovic, 2005). The total
length of capillaries in human brain is about 400 miles, and the
capillary surface area available for molecular transport is about
20 m2 (Begley and Brightman, 2003). The thickness of the cere-
bral endothelial membrane is 0.2 to 0.3 mm. The length of brain
capillaries is reduced in neurodegenerative disorders, as for
example in Alzheimer’s disease (AD) (Bailey et al., 2004; Wu
et al., 2005). These vascular reductions can diminish transport
Neuron
Reviewof energy substrates and nutrients across the BBB, and reduce
the clearance of potential neurotoxins from the brain, as dis-
cussed below.
Figure 2A illustrates a vascular cast of the mouse brain dem-
onstrating the rich network of blood vessels that continues at
the level of brain capillaries (Figure 2B). In vivo multiphoton imag-
ing of cortical blood flow in mice expressing green fluorescent
protein (GFP) in the brain endothelium shows that virtually all
brain microvessels are constantly perfused at any time (Fig-
ure 2C). The former ‘‘capillary recruitment’’ hypothesis, propos-
ing opening of new capillaries from an increase in the CBF and
closing of brain capillaries from a decrease in the CBF (Weiss,
1988), has thus been modified to a ‘‘functional recruitment’’ hy-
pothesis: brain capillaries are perfused all the time, but they tran-
sition from low to high blood flow with an increase in the CBF, or
from high to low blood flow with a decrease in the CBF (Kuschin-
sky and Paulson, 1992). As shown in rodent models of brain hyp-
oxemia, the major mechanisms raising the CBF are increased
velocity of microvessel perfusion (Bereczki et al., 1993) and
recruitment of red blood cells to the capillary networks (Krolo
and Hudetz, 2000).
The morphometric analysis of the mouse cortical vasculature
in vivo based on two-photon imaging indicates that perfused
capillaries (4–8 mm in diameter) and small arterioles and venules
(10–60 mm in diameter) occupy between 3%–4% and 4%–6% of
the brain volume, respectively. This correlates well with some in
vivo measurements of the blood volume in the gray matter in
human brain determined by magnetic resonance imaging (MRI)
(Rengachary, 2005).
BBB Cellular Junctions
The BBB is composed of a tightly sealed monolayer of BEC, which
normally precludes free exchanges of solutes between blood and
brain and brain and blood (Ohtsuki and Terasaki, 2007). An excep-
tion to this rule are small lipid-soluble molecules <400 Da with
fewer than nine hydrogen bonds, which can cross the BBB unas-
sisted, via lipid-mediated diffusion (Pardridge, 2007). All drugs
presently in clinical use for CNS therapy are small molecules
that have these characteristics. Lipid mediation of small mole-
cules through biological membranes requires molecular move-
ment through channels of a finite size within the lipid bilayer.
BEC are normally connected at a junctional complex by the TJ
and adherens junctions (AJ) (Hawkins and Davis, 2005). Gap
Figure 1. The Blood-Brain Barrier, or BBB, to Trypan Blue and Its
Diffusion from the Cerebrospinal Fluid, or CSF, into the Brain
(A) Goldmann’s first experiment. Trypan blue (dye) was injected into the blood.
Brain and CSF were analyzed.
(B) Goldmann’s second experiment. Dye was injected into the CSF. Brain and
blood were analyzed.
(C) Conclusions from the two experiments.junctions have also been identified at the BBB (Nagasawa
et al., 2006), but their role in the barrier function is not clear. The
TJ primarily confer the low paracellular permeability and high
electrical resistance of the BBB (Bazzoni and Dejana, 2004). Pos-
sible roles of different TJ proteins in the pathogenesis of various
brain disorders are discussed below.
Tight Junctions
The molecular biology of the TJ is quite complex (Wolburg,
2006). The TJ proteins and their adaptor molecules, which link
the TJ to the cytoskeleton, are often affected during acute and
chronic diseases of the brain. Figure 3A shows the molecular or-
ganization of the BBB TJ, which form a continuous cellular mem-
brane that restricts transport of molecules between blood and
the brain interstitial fluid (ISF), and vice versa.
Occludin. Occludin was the first integral membrane protein
discovered within the TJ of endothelial cells, including the
BBB. A deletion construct lacking the N terminus and extracellu-
lar domains of occludin exerted a dramatic effect on the TJ integ-
rity (Bamforth et al., 1999). Cell monolayers failed to develop an
efficient permeability barrier, as demonstrated by low transcellu-
lar electrical resistance, an increased paracellular flux to small
molecular mass tracers, and the presence of gaps in the P-
face associated TJ strands on the freeze-fracture EM analysis.
These findings demonstrated that the N-terminal half of occludin
had an important role in maintaining a TJ assembly and the
barrier function.
Deletion of occludin in mice results in a complex phenotype
and postnatal growth retardation (Saitou et al., 2000). Surpris-
ingly, the TJ themselves are not affected by the lack of occludin,
as demonstrated by well-developed networks of TJ strands
and normal transepithelial electrical resistance. Likely, normal
Figure 2. A Cast of the Microvascular Network and Two-Photon
In Vivo Imaging of the Mouse Brain Microcirculation
(A) Vascular cast of a mouse cortex. Mouse was infused via carotid artery with
methyl metacrylate. To obtain a corrosive cast, brain tissue was dissolved with
potassium hydroxide.
(B) Scanning electron micrograph of microvessels from the cast in (A).
(C) Cortical microcirculation in Tie-2-GFP-expressing mice studied in vivo by
two-photon in vivo imaging. (Left) GFP (green) is localized exclusively to the
brain endothelium. (Middle) Intravenously injected intravascular marker
tetra-meta rhodamine (TMR, mw = 70 kDa, red) remains restricted within brain
microvessels by the BBB. (Right) Merged left and middle panels indicate that
all cortical microvessels were perfused with TMR. A two-photon image of the
parietal cortex was taken through the thinned skull at a depth of 50 mm.
(A) and (B), courtesy of Dr. Yaoming Wang, and (C), courtesy of Rachal Love
from B.V. Zlokovic laboratory.Neuron 57, January 24, 2008 ª2008 Elsevier Inc. 179
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claudin-3, zonula occludens-1 (ZO-1), ZO-2, vascular endothe-
lial cadherin (VE-cadherin), and a-catenin may compensate
well for occludin loss (Saitou et al., 2000). However, hyperplasia
of the gastric epithelium, calcifications in the brain, and testicular
atrophy found in occluding-deficient mice (Saitou et al., 2000)
raise a possibility that occludin has some other important phys-
iological roles beyond its function as a TJ protein. Indeed, recent
studies have demonstrated that occludin regulates epithelial cell
differentiation (Schulzke et al., 2005). In addition, it controls clau-
din-2-dependent TJ function, as well as cell apoptosis through
inhibition of mitogen-activated protein kinases (MAPK) and Akt
signaling pathways (Murata et al., 2005). Whether occludin has180 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.a role in the BBB differentiation during normal development,
brain vascular repair, or both remains to be explored.
Recent studies of mice with experimental autoimmune en-
cephalomyelitis (EAE), a model of multiple sclerosis (MS), have
shown that occludin dephosphorylation precedes visible signs
of disease and happens just prior to apparent changes in the
BBB permeability (Morgan et al., 2007). These findings suggest
that occludin could be a target for signaling processes in EAE
and that it may regulate the response of the BBB to the inflam-
matory environment, as seen in MS.
Treatment of mice with Tat protein results in decreased expres-
sionof occludinand ZO-1 (Pu et al., 2007). Tat is normally released
from human immunodeficiency virus type 1 (HIV-1)-infectedFigure 3. A Simplified Molecular Atlas of the BBB
(A) Tight junctions. Claudins (claudin-3, -5, and -12) and occludin have four transmembrane domains with two extracellular loops. The junctional adhesion mol-
ecule A (JAM-A) and the endothelial cell-selective adhesion molecule (ESMA) are members of the Ig superfamily. Zonula occludens proteins (ZO-1, ZO-2, and ZO-3)
and the calcium-dependent serine protein kinase (CASK) are first-order cytoplasmic adaptor proteins that contain PDZ binding domains for the C terminus of the
intramembrane proteins. Cingulin, multi-PDZ protein 1 (MUPP1), and the membrane-associated guanylate kinase with an inverted orientation of protein-protein
interaction domain (MAGI) are examples of second-order adaptor molecules. The first- and second-order adaptor molecules together with signaling molecules
control the interaction between the intramembrane proteins and actin/vinculin-based cytoskeleton. Adherens junctions. The vascular endothelial cadherin
(VE-cadherin) is the key molecule. Platelet endothelial cell adhesion molecule 1 (PECAM-1) mediates homophilic adhesion. Catenins (a, b, c) link adhesion junc-
tions to actin/vinculin-based cytoskeleton.
(B) Carrier-mediated transporters. GLUT1, glucose transporter, and monocarboxylate transporter 1 (MCT1) for lactate exist at both the luminal and the abluminal
membranes. All essential amino acids (AA) are transported by the L1 and y+ systems on each membrane. Five Na+-dependent transport systems mediate elim-
ination of nonessential AA (ASC, A), essential AA (LNAA), the excitatory acidic AA (EAAT) (e.g., glutamate and aspartate), and nitrogen-rich AA (N) (e.g., glutamine)
from the brain. Facilitative transporters xG
 and n on the luminal membrane mediate glutamate, aspartate, and glutamine efflux to blood. Ion transporters. The
sodium pump (Na+, K+-ATPase) on the abluminal membrane controls Na+ influx and K+ efflux. Sodium-hydrogen exchanger on the luminal membrane is a key
regulator of intracellular pH. Na+-K+-2Cl– cotransporter is on the luminal membrane. The chloride-bicarbonate exchanger exists on each membrane.
(C) Active efflux transporters. Multidrug efflux transporters at the luminal membrane limit drug uptake into the brain. Transporters at the abluminal membrane
could act in concert with luminal transporters to eliminate drugs from brain ISF. P-gp is expressed on each membrane. Breast cancer resistance protein
(BCRP) is on the luminal membrane. Multidrug resistance-associated proteins (MRPs) are expressed mainly on the luminal membrane. Organic anion transport-
ing polypeptide (OATP) 2 and 3 exist on the luminal and abluminal membranes, respectively. Organic anion transporter 3 (OAT3) is on the abluminal membrane.
Peptide transporters and caveolae. Peptide transport system 1 (PTS-1) on the abluminal membrane mediates efflux of opioid peptides (e.g., enkephalins) from
brain. PTS-2 mediates efflux of arginine-vasopressin (AVP). PTS-4 on the luminal membrane requires the vasopressinergic receptor 1 (V1) to transport AVP into
the brain. Receptors for insulin (IR) and transferrin (TFR) are found in the caveolar membranes. Caveolin-1 (Cav-1) could be associated with receptors (e.g., TFR),
tight junctions (TJ), or growth factor receptors, such as vascular endothelial growth factor receptor (Flk-1).
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providing potential entry for HIV-1 into the brain. Tat-induced loss
of occludin and ZO-1, and the resulting loss of the TJ integrity, can
be implicated in the pathogenesis of HIV-1-related brain
diseases.
Occludin is also vulnerable to attack by matrix metalloprotei-
nases (MMPs) (Rosenberg and Yang, 2007). Reperfusion injury
in rodent models of stroke leads to a biphasic opening of the
BBB, with the early opening occurring several hours after the on-
set of reperfusion due to activation of the constitutive enzyme
gelatinase A (MMP-2). This initial opening is transient and fol-
lowed 24 to 48 hr later by more intense damage to the blood ves-
sel, which is associated with the expression and activation of ge-
latinase B (MMP-9) and stromelysin-1 (MMP-3). MMPs can also
degrade basal lamina proteins such as fibronectin, laminin, and
heparan sulfate after an ischemic insult, which contributes to the
BBB breakdown (Cheng et al., 2006; Zlokovic, 2006).
Accumulation of occludin in neurons, astrocytes, and micro-
glia in AD, frontotemporal dementia, and vascular dementia
has also been reported (Romanitan et al., 2007), suggesting pos-
sible new functions of occludin and the TJ proteins in the patho-
genesis of these dementias. Their exact role in dementia-related
pathologies, however, remains to be elucidated, as discussed
below.
Claudins. The claudins are a multigene family of more than
20 members that form TJ strands through homophilic claudin-
claudin interactions mediated by the extracellular loop 2 of clau-
dins (Piontek et al., 2008). Claudin-5, -3, and -12 are localized at
the BBB (Nitta et al., 2003; Wolburg, 2006), whereas the pres-
ence of claudin-1 is controversial (Lee et al., 2003). Each claudin
regulates the diffusion of a group of molecules of a certain size.
For example, mice with claudin-5 deletion die as neonates due to
a size-selective loosening of the BBB for molecules <800 Da
(Nitta et al., 2003).
Selective downregulation of claudin-8 by kindling epilepsy
(Lamas et al., 2002) suggests that selective modulation of clau-
din expression in response to abnormal neuronal synchroniza-
tion may lead to BBB breakdown and brain edema, as seen in
epilepsy.
Claudin-5 is degraded by MMP-2 and MMP-9 after an ische-
mic insult, and both claudin-5 and occludin were found in the
surrounding astrocytes, but not in the brain endothelium, after
the BBB disruption (Yang et al., 2007). It is possible that increased
levels of occludin found in astrocytes and neurons in vascular
dementia, AD, and frontotemporal dementia (Romanitan et al.,
2007) might reflect the autophagy of the TJ proteins by the
surrounding cells after the BBB breakdown caused by chronic
hypoxia, aberrant angiogenesis, or both (Wu et al., 2005).
As with occludin, exposure of BEC to HIV-1 Tat protein de-
creases expression and alters distribution of claudin-5, which in
turn may contribute to BBB disruption in the course of HIV-1 in-
fection, and the entry of HIV-1 into the brain (Andras et al., 2005).
Other Junctional Proteins. Junctional adhesion molecule A
(JAM-A) (Bazzoni et al., 2005) and the endothelial cell-selective
adhesion molecule (ESAM) (Nasdala et al., 2002) are members
of the immunoglobulin (Ig) supergene family. A recent study in
spontaneously hypertensive rats has suggested that JAM-A is
upregulated throughout the body compared with the controlrats, and that this is not secondary to the hypertension (Waki
et al., 2007). When JAM-A is expressed in the nucleus tractus
solitarii, it raises arterial pressure, suggesting a prohypertensive
role of this TJ protein in the brain stem. It has been suggested
that altered expression of JAM-A, in addition to affecting the
junctional tightness, may also affect leukocyte trafficking, with
implications for immune status within the diseased CNS (Padden
et al., 2007). The role of JAM-A and ESAM in different brain
pathologies is still relatively poorly understood.
Cytoskeleton Link
ZO-1 Proteins. The integral membrane proteins of the TJ are
linked to the cytoskeleton via cytoplasmic multidomain scaffold-
ing proteins of the peripheral membrane-associated guanylate
kinase (MAGUK) family, such as ZO-1, ZO-2, and ZO-3 (Hawkins
and Davis, 2005). Besides providing the cytoskeletal anchorage
for the transmembrane TJ proteins, the MAGUK also control
correct spatial distribution of claudins though their PDZ binding
domains.
Significant differences in the incidences of TJ abnormalities re-
lated to reduced ZO-1 expression have been detected between
different types of lesions in MS, and between MS and control
white matter (Kirk et al., 2003). It has been shown that about
42% of vessel segments in active MS plaques have reduced
ZO-1 expression with severe plasma leakage, while about 23%
of vessels in inactive plaques also demonstrate reduced ZO-1
protein levels. It has been suggested that persistent endothelial
abnormalities associated with BBB leakage may contribute to
MS progression and have prognostic implications, and should
be considered when planning disease-modifying therapy (Leech
et al., 2007).
In a model of experimental diabetes in rats, the BBB perme-
ability to 14C-sucrose increases concurrently with decreased
production of ZO-1 and occludin at the BBB (Hawkins et al.,
2007). Degradation of these two TJ proteins has been related
to an increased plasma MMP activity, suggesting that peripheral
MMPs, in addition to central MMPs, could be targets for stabiliz-
ing BBB dysfunction. Since MMPs also participate in regulating
neurogenesis and angiogenesis, as for example during a repair
phase after stroke (Zhao et al., 2006), more work is needed to
clarify the therapeutic potential of MMP inhibition in different
brain pathologies.
It has been demonstrated that caveolin-1 regulates expression
of occludin and ZO-1 in BEC monolayers, a model of an in vitro
BBB (Song et al., 2007a). Loss of caveolin-1 facilitates the ability
of the chemokine CCL2, formerly called monocyte chemoattrac-
tant protein-1 (MCP-1), to permeablize the BBB. Thus, caveolin-1
may be critical in regulating inflammation at the BBB, and there-
fore could represent a novel therapeutic target for stabilizing the
BBB.
Actin. The importance of the cytoskeleton in establishing and
maintaining the BBB has become evident from studies in mice
lacking the actin-binding protein dystrophin, i.e., the mdx mice
(Nico et al., 2003). These mice exhibit an increase in the brain
vascular permeability due to disorganized a-actin cytoskeleton
in endothelial cells and astrocytes, as well as altered subcellular
localization of junctional proteins in the endothelium and the wa-
ter channel aquaporin-4 in the astrocytic endfeet. These findings
demonstrate that properly arranged actin filaments and theirNeuron 57, January 24, 2008 ª2008 Elsevier Inc. 181
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function.
HIV-1 gp120 and alcohol can reorganize the cytoskeleton and
induce stress fiber actin formation, causing increased perme-
ability of the human BBB endothelium (Shiu et al., 2007). It has
been suggested that alcohol-mediated changes in the BEC
monolayers may increase diffusion of plasma components and
viral penetration across the BBB, and therefore, especially at
levels attained in heavy drinkers, accelerate HIV-1 penetration
into the brain.
Adherens Junctions
The AJ are typically found intermingled with the TJ.
VE-cadherin. Within the AJ, the endothelial-specific integral
membrane protein VE-cadherin is linked to the cytoskeleton via
catenins, which belong to the family of armadillo proteins (Baz-
zoni and Dejana, 2004). At the BBB, expression and localization
of b-catenin, c-catenin, and p120cas is crucial for the functional
state of the AJ.
Caveolin-1-induced reductions in ZO-1 and occludin expres-
sion are associated with comparable alterations in the AJ pro-
teins, VE-cadherin, and b-catenin, which may enhance CCL2-
medited stimulation of transendothelial migration of monocytes
(Song et al., 2007a). Therefore, changes in the AJ proteins may
potentially contribute to increased paracellular BBB permeability
and leukocyte trafficking in the CNS. On the other hand, b-cate-
nin expression is not altered in MS lesions (Padden et al., 2007),
which would argue against the role of AJ in MS pathogenesis.
Recent in vitro and in vivo data show that VE-cadherin is re-
quired for endothelial integrity in quiescent vessels and for the
correct organization of new vessels (Lampugnani and Dejana,
2007). Several mechanisms by which VE-cadherin may regulate
endothelial functions have been proposed, such as (1) direct
activation of signaling molecules with a role in survival and orga-
nization of the actin cytoskeleton (e.g., PI3 kinase and Rac); (2)
regulation of gene transcription cofactors (e.g., b-catenin and
p120); and (3) formation of complexes with growth factor recep-
tors, as, for example, with the vascular endothelial growth factor
(VEGF) receptor 2 (VEGFR-2) (also called Flk-1), and modulation
of VEGFR-2 signaling. The role of AJ in chronic neurodegenera-
tive disorders with documented functional and morphological
changes at the BBB, such as AD, Parkinson’s disease (PD),
MS, and others, remains mainly unexplored.
PECAM-1. Platelet endothelial cell adhesion molecule 1 (PE-
CAM-1), also known as CD31, is localized in the endothelial cell
contacts outside of the TJ. PECAM-1 is a major participant in
the migration of leukocytes across endothelium.
A chimeric, soluble form of PECAM-1 fused to human IgG-Fc
fragment (sPECAM-Fc) impairs migration of lymphocytes across
the brain endothelial monolayers and diminishes the severity of
EAE in a mouse model (Reinke et al., 2007). These findings sug-
gest a therapeutic potential of the sPECAM-Fc construct for
short-term treatments of diseases like MS.
A recombinant construct targeting a single-chain variable
fragment (scFv) for urokinase-type plasminogen activator (uPA)
to stably expressed PECAM-1 (anti-PECAM-1 scFv-uPA) accu-
mulates in the brain after intravascular injection, while unconju-
gated uPA does not (Danielyan et al., 2007). It lyses clots in the
cerebral arterial vasculature without hemorrhagic complications182 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.and provides rapid and stable cerebral reperfusion. It has been
suggested that effective and safe thromboprophylaxis in the ce-
rebral arterial circulation by anti-PECAM-1 scFv-uPA represents
a prototype of a new heuristic to prevent recurrent cerebrovas-
cular thrombosis by using molecules expressed at the BBB as
therapeutic targets. More research is needed to explore the full
therapeutic potential of this novel approach.
PECAM-1 and the receptor for advanced glycation end prod-
ucts (RAGE) are required for AD amyloid b-peptide (Ab)-medi-
ated migration of monocytes across human BEC monolayers
(Giri et al., 2000). Whether blocking PECAM-1 would have a po-
tential therapeutic benefit in AD, and in other brain pathologies
associated with peripheral leukocyte infiltration, remains to be
determined.
BBB Transport Systems
The TJ-controlled paracellular impermeability of the brain capil-
lary endothelium implies that the hydrophilic molecules must
cross the endothelial wall transcellularly to reach their neuronal
targets or leave the brain (Deane and Zlokovic, 2007). In general,
transcellular bidirectional transport across the BBB can be clas-
sified into five main categories: carrier-mediated transport, ion
transport, active efflux transport, receptor-mediated transport,
and caveolae-mediated transport.
Carrier-Mediated Transport
Specific, carrier-mediated transport systems facilitate transport
of nutrients such as hexoses (glucose, galactose); neutral, basic,
and acidic AA and monocarboxylic acids (lactate, pyruvate,
ketone bodies); nucleosides (adenosine, guanosine, uridine); pu-
rines (adenine, guanine); amines (choline); and vitamins (Hawkins
et al., 2006; Simpson et al., 2007; Ohtsuki and Terasaki, 2007;
Deeken and Loscher, 2007; Spector and Johanson, 2007). The
concentration gradients for nutrients are generally in the direc-
tion from blood to brain. These are regulated by brain metabolic
needs, and by the concentrations of substrates in plasma.
GLUT1 glucose transporter, the L1 large neutral amino acid
transporter, the CNT2 adenosine transporter, and the monocar-
boxylate transporter 1 (MCT1) have been cloned from BBB-spe-
cific cDNA libraries (Pardridge, 2005).
GLUT1. The glucose transporter GLUT1 is of special impor-
tance because glucose is the main energy source for the brain
(Qutub and Hunt, 2005; Simpson et al., 2007). GLUT1 (mw =
55 kDa) is a member of a gene family of sodium-independent glu-
cose transporters, which is expressed exclusively at the BBB.
GLUT1 transports glucose and other hexoses across the BBB
(Figure 3B). The density of GLUT1 transporters at the abluminal
membrane is higher than at the luminal (Simpson et al., 2007).
The asymmetrical distribution of GLUT1 at the BBB provides
a homeostatic control for glucose influx into the brain by prevent-
ing glucose accumulation in the brain ISF at levels higher than
those in the blood.
Heterozygous mutations or hemizygosity of the GLUT1 gene
cause GLUT1 deficiency syndrome. GLUT1 deficiency syndrome
in humans is characterized by infantile seizures, developmental
delay, and acquired microcephaly. It is caused by haploinsuffi-
ciency of the BBB hexose carrier. GLUT1+/ mice that have
been generated by the targeted disruption of the promoter and
exon 1 regions of the mouse GLUT1 gene have epileptiform
Neuron
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incoordination, microencephaly, decreased brain glucose up-
take, and substantially decreased brain GLUT1 expression in
brain capillaries (Wang et al., 2006). Human GLUT1 deficiency
syndrome and the mouse model are perfect examples of brain
disorders triggered by dysfunctional BBB transporters.
The expression of GLUT1 is controlled by hypoxia-inducible
factor-1 (HIF-1), a transcription factor which regulates the adap-
tive responses to hypoxia. HIF-1a accumulates in the rat cere-
bral cortex after transient global ischemia, which is associated
with corresponding increases in GLUT1 and other HIF-1a target
genes (Chavez and LaManna, 2002). The adult rat brain adapts
to prolonged moderate hypoxia with increased vascularity and
increased GLUT1 density at the BBB (Harik et al., 1996).
GLUT1 protein expression in brain capillaries is reduced in AD,
although this is not associated with changes in the GLUT1 mRNA
structure (Mooradian et al., 1997) or the levels of GLUT1 mRNA
transcripts (Wu et al., 2005). The surface area at the BBB avail-
able for glucose transport is substantially reduced in AD (Bailey
et al., 2004; Wu et al., 2005). These findings suggest that the AD
brain is subjected to a continuous shortage in energy metabo-
lites due to GLUT1 deficiency at the BBB.
Indeed, recent PET studies with (18)F-2-fluoro-2-deoxy-D-glu-
cose (FDG) have demonstrated that individuals diagnosed with
aging-associated cognitive decline have significantly reduced
glucose uptake in the right precuneus, posterior cingulate, right
angular gyrus, and bilateral middle temporal cortices prior to
conversion into AD (Hunt et al., 2007). These respective deficits
are more pronounced in AD patients and involve the frontal cor-
tices. Thus, individuals with mild cognitive impairment (MCI)
have reduced glucose transport across the BBB prior to neuro-
degeneration and brain atrophy.
Subsequent FDG-PET studies have confirmed that the re-
duced FDG uptake by the posterior cingulate gyri and parieto-
temporal lobes in AD patients is not due to brain atrophy (Samur-
aki et al., 2007). A longitudinal study using FDG-PET imaging
with the follow-up PET exams has suggested that reductions
of glucose utilization by the hippocampus during normal aging
can predict cognitive decline years in advance of the clinical di-
agnosis (Mosconi et al., 2008). Consistent with this concept, pre-
symptomatic early-onset autosomal dominant familial AD (FAD)
individuals carrying mutations in the presenilin-1 gene show
widespread AD-like reductions in FDG utilization in the absence
of structural brain atrophy (Mosconi et al., 2006).
In sum, the FGD-PET measures may serve as early biomarkers
for the preclinical diagnosis of AD. But more than that, these stud-
ies suggest the reductions in glucose uptake across the BBB may
precede the neurodegenerative process and brain atrophy in the
MCI cases converting to AD. Whether GLUT1 at the BBB can be
manipulated therapeutically to prevent the development of de-
mentia and control a chronic neurodegenerative process remains
to be explored. Future studies are likewise needed to increase
preclinical specificity in differentiating the types of dementias
based on the reduced glucose uptake across the BBB.
MCT1. Ketone bodies, such as R-beta-hydroxybutyrate and
acetoacetate, are energy sources for the brain. As with glucose
metabolism, monocarboxylate uptake by the brain is dependent
on the function and regulation of its own transporter system.MCT1 is expressed at each membrane of the BBB (Simpson
et al., 2007). MCT1 mediates transport of lactate and other mono-
carboxylates in and out of the brain (Figure 3B). Recent studies in
diet-induced ketotic rats have demonstrated a substantial upre-
gulation of MCT1 and GLUT1 at the BBB, associated with an
increased extraction of plasma ketone bodies by the brain, but
no changes in CBF (Puchowicz et al., 2007). These findings sug-
gest that upregulation of the BBB transporters (e.g., MCT1 and
GLUT1), but not an increase in CBF, is critical for adapting brain
metabolism to energy metabolites available in the plasma.
Amino Acid Transporters. The existence of two facilitative
transporters for AA, i.e., L1 and y+, on luminal and abluminal
membranes, provides the brain access to all essential AA (Haw-
kins et al., 2006). The sodium-independent L1 facilitative trans-
porter mediates transport of large neutral essential AA (e.g.,
leucine, isoleucine, valine, tryptophan, tyrosine, phenylalanine,
threonine, and methionine). The y+ system mediates transport
of cationic AA, some of which are essential in the brain (i.e., ly-
sine), and some of which are nonessential in the adult brain
(e.g., arginine and ornithine) but are essential during a juvenile
period, as for example L-arginine, a precursor of nitric oxide
(NO) (Figure 3B).
Five sodium-dependent transporters for AA exist at the ablu-
minal membrane (Figure 3B). The abluminal systems have the
capability to actively transfer every naturally occurring AA from
the brain ISF to endothelial cells, and from there, into the circu-
lation. This provides a mechanism by which AA concentrations
in the brain ISF are maintained at approximately 10% of those
in plasma. For example, the ASC and A systems at the BBB
transport nonessential AA out of the brain.
The sodium-dependent system for the excitatory acidic AA
(EAAT), e.g., glutamate and aspartate, provides a mechanism
for net removal of potentially neurotoxic AA from the brain. It
also accounts for the low penetration of glutamate into the brain.
Excitotoxicity is defined as excessive exposure to the neuro-
transmitter glutamate or overstimulation of its membrane recep-
tors, leading to neuronal injury or death (Lipton, 2005). Excess
glutamate in brain fluids characterizes acute brain insults such
as traumatic brain injury and stroke. In addition, it has been sug-
gested that glutamate excitotoxcity is implicated in the neurode-
generative process in epilepsy (Alexander and Godwin, 2006),
amyotrophic lateral sclerosis (ALS) (Van Damme et al., 2005),
MS (Vallejo-Illarramendi et al., 2006), Huntington’s disease
(HD) (Cowan and Raymond, 2006), and AD (Lipton, 2005).
Glutamate transporters EAAT1, EAAT2, and EAAT3 determine
the levels of extracellular glutamate and are essential to prevent
excitotoxicity (Lipton, 2005). It has been demonstrated that
scavenging glutamate in the blood increases the efflux of excess
glutamate from the brain. For example, systemic treatment of
rats with oxalocaetate, a glutamate scavenging agent, prior to
or early after closed brain injury can afford brain neuroprotection
by reducing the level of glutamate in the blood, which promotes
efflux of glutamate from the brain (Zlotnik et al., 2007). Whether
the BBB EAAT glutamate transporter can be targeted therapeu-
tically to reduce glutamate levels in acute and chronic neurode-
generative disorders remains to be explored.
The sodium-dependent system for nitrogen-rich AA removes
glutamine and other nitrogen-rich AA (e.g., histidine andNeuron 57, January 24, 2008 ª2008 Elsevier Inc. 183
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nal side, xG
 and n, mediate transport of acidic AA and nitrogen-
rich AA from the endothelium to blood, respectively (Figure 3B).
Vitamins. The vitamins are transported in most cases by sep-
arate carriers through the BBB or choroid plexus, as, for exam-
ple, vitamins B1, B3, B5, or E (Spector and Johanson, 2007).
The exception is the sodium-dependent multivitamin transporter
for biotin, pantothenic acid, and lipoic acid.
Ion Transporters
The BBB has a high density of mitochondria, which reflects high
energy demands for active ATP-dependent transporters such as
the sodium pump (Na+, K+-ATPase). The sodium pump is local-
ized on the abluminal membrane (Vorbrodt, 1988) (Figure 3B). It
regulates sodium influx into the brain ISF in exchange for potas-
sium. Na+, K+-ATPase maintains the high concentration gradient
for Na+ at the BBB (extracellular > > intracellular), so that Na+-
dependent transport can occur. Sodium-potassium-two chlo-
ride (Na+-K+-2Cl) cotransporter resides predominantly in the
luminal BBB membrane (O’Donnell et al., 2006). Na+-K+-2Cl
cotransporter transports sodium, potassium, and chloride from
blood into the brain endothelium. Sodium-hydrogen exchanger
is expressed on the luminal membrane, whereas chloride-bicar-
bonate exchanger is expressed at each side (Taylor et al., 2006).
These two transporters play critical roles in regulating intracellu-
lar pH in the endothelium. The chloride-bicarbonate exchanger
also regulates active secretion of bicarbonate across the BBB.
The sodium-calcium exchanger is also present at the BBB. In
the forward mode (Na+ entry/Ca2+ extrusion), this exchanger
mediates Ca2+ efflux from the endothelium. In the presence of
altered Na+ gradients or under pathological circumstances, it
may transport calcium into the endothelium.
Active Efflux
Efflux of molecules from the brain endothelium can be initiated at
the luminal membrane, as in the case of the ATP-binding cassette
(ABC) transporters (Hermann and Bassetti, 2007). The multidrug
resistance transporter P-glycoportein (P-gp) is an ATP-depen-
dent efflux pump which mediates rapid removal of ingested toxic
lipophilic metabolites, such as many amphipatic cationic drugs
(Loscher and Potschka, 2005; Hermann and Bassetti, 2007).
P-gp is encoded in humans by the MDR1 gene and in rodents
by the mdr1a and mdr1b genes. In addition to P-gp, several mul-
tidrug resistance-associated proteins (MRPs) are expressed in
the brain microvessels. The MRPs, including the breast cancer
resistance protein (BCRP) and members of the organic anion
transporting plypeptide (OATP) family and the organic anion
transporter (OAT) family, mediate mainly the efflux of anionic
compounds (Figure 3C). These transporters have the potential
to work together to reduce penetration of many drugs into the
brain and increase their efflux from the brain.
Recent immunogold cytochemistry EM studies in rat and hu-
man brain tissue revealed that P-gp is expressed at the luminal
and abluminal membrane, as well as in pericytes and astrocytes
(Bendayan et al., 2006). Subcellularly, P-gp is distributed along
the nuclear envelope, in caveolae, cytoplasmic vesicles, Golgi
complex, and rough endoplasmic reticulum.
The possible role of the ABC transporters in the pathogenesis
and treatment of different brain disorders such as epilepsy or PD
is increasingly recognized. For example, one-third of patients184 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.with epilepsy have drug-resistant epilepsy, which is associated
with an increased risk of death and debilitating psychosocial con-
sequences. A positive association between the polymorphism in
the MDR1 gene encoding P-gp (or ABCB1) and multidrug-resis-
tant epilepsy has been reported in a subset of epilepsy patients
(Siddiqui et al., 2003). However, the follow-up association genet-
ics studies did not support a major role for this polymorphism, as
recently reviewed (Tate and Sisodiya, 2007). Future association
genetics studies are needed to understand better whether P-gp
or some other members of the multidrug transporter gene family
at the BBB are involved in multidrug-resistant epilepsy and other
epilepsy phenotypes. Finally, as discussed below, it has been
suggested that mutation of the MDR1 gene may predispose car-
riers to damaging effects of pesticides and possibly other toxic
xenobiotics transported by P-gp, leading to a PD phenotype
(Droz´dzik et al., 2003).
Peptide and Protein Transport
The peptide bond prevents dipeptides from using the L1 amino
acid facilitative transport system (Zlokovic et al., 1983). However,
the endothelial cells at the BBB express several transport sys-
tems for neuroactive peptides, such as arginine-vasopressin
(AVP) (Zlokovic et al., 1990), enkephalins (Zlokovic et al., 1987,
1989), tyrosine melanocyte-stimulating inhibitory factor 1 (Tyr-
MIF-1), delta-sleep inducing peptide (DSIP), luteinizing-hormone
releasing hormone (LHRH), and some cytokines and chemokines
(Zlokovic, 1995; Banks, 2006). Peptide transport system 1
(PTS-1) and 2 (PTS-2) at the abluminal membrane mediate efflux
of enkephalins/Tyr-MIF-1 and AVP, respectively, from the brain
to the blood (Banks, 2006) (Figure 3C). PTS-3, on the luminal
membrane, transports peptide T into the brain. PTS-4 transports
LHRH bidirectionally. The V1-vasporessinergic receptor is re-
quired for transport of AVP from blood to the brain (Zlokovic
et al., 1990). Since enkephalins are transported in the liver by
the OATP transporters, and since transport of endorphins is im-
paired in P-gp null mice, it would be of interest to determine the
overlap between PTS-1 and OATP at the BBB, and the role of
P-gp in the efflux of enkephalins across the BBB.
Large proteins, such as transferrin (Jefferies et al., 1984), low-
density lipoproteins (LDL) (Meresse et al., 1989), leptin (Zlokovic
et al., 2000a), immunoglobulin G (IgG) (Deane et al., 2005), insulin,
and insulin-like growth factor (Pardridge, 2005) use receptor-me-
diated transport systems to cross the BBB. To date, the leptin
BBB receptor (OBR) and the transferrin BBB receptor have
been cloned (Pardridge, 2005) (Figure 3C). Receptor-mediated
transport systems at the BBB have been used as targets for
drug delivery to the brain via a strategy known as Trojan horses:
different growth factors or anti-sense agents that normally do not
cross the BBB, or immunoliposomes carrying naked DNA, can be
conjugated to monoclonal antibodies against one of the BBB re-
ceptors (e.g., insulin and transferrin). The monoclonal antibodies
act as surrogate ligands and can be used to carry conjugated
neurotherapeutics across the BBB (Pardridge, 2007).
The rates of carrier-mediated or receptor-mediated transcyto-
sis of peptides and proteins across the BBB are typically three
orders of magnitude lower compared with large neutral AA (Zlo-
kovic et al., 1985). It is of note that several neuroactive peptides
and proteins are active in the brain at low concentrations. Thus,
slow transport rates from blood to brain may act to limit the
Neuron
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circulating peptides by the brain can be compared with uptake of
drugs such as acetaminophen, which exerts analgesic activity
with an uptake of only 0.2%/g brain, or morphine, which has
an uptake of <0.02%/g.
Caveolae
Raft-dependent endocytosis is cholesterol sensitive, clathrin in-
dependent internalization of ligands and receptors from the
plasma membrane (Lajoie and Nabi, 2007). It encompasses en-
docytosis of caveolae, smooth plasmalemmal vesicles that form
subdomains of cholesterol and sphingolipid-rich rafts that are
enriched in caveolin-1. The caveolae control transcellular per-
meability by regulating endocytosis, transcytosis, and signaling
in lipid-based microdomains of the BBB (Parton and Richards,
2003). The caveolar membranes contain receptors for transfer-
rin, insulin, albumin, ceruloplasmin, RAGE, LDL, HDL, interleu-
kin-1, and vesicle-associated membrane protein-2 (Wolburg,
2006) (Figure 3C). Signaling complexes at caveolin-1 include
heterotrimeric G proteins, members of the MAPK pathway, src
tyrosine kinase, protein kinase C, and the endothelial NO syn-
thase. The involvement of caveolin-1 in NO and calcium signaling
has been demonstrated in caveolin-1-deficient mice (Drab et al.,
2001). VEGFR-2 (Labrecque et al., 2003) and P-gp (Jodoin et al.,
2003) are also closely associated with caveolin-1. Caveolin-1
can also influence the levels of TJ proteins in BEC (Song et al.,
2007a). The role of caveolae in BBB functions in health and dis-
ease remains to be explored.
Enzymatic BBB
Endothelial cells of the BBB provide a metabolic barrier by ex-
pressing a number of enzymes that modify endogenous and ex-
ogenous molecules, which otherwise could bypass the physical
barrier and negatively affect neuronal function (Pardridge, 2005).
The capillary endothelium, pericytes, and astrocytes expressa variety of ectoenzymes on the plasma membranes, including
aminopeptidases, endopeptidases, cholinesterase, and others.
Passive Transport by the Brain Fluids
Brain ISF-CSF ‘‘bulk flow’’ mediates transport of molecules into
the CSF at a slow rate, irrespective of their size (Davson, 1976;
Zlokovic, 2005). The CSF acts as a sink for potentially toxic
molecules and metabolic waste products. Toxic molecules and
metabolic waste products are removed from the CSF back
into the circulation by active transport or facilitated diffusion
across the choroid plexus epithelium, or by vacuolar transport
across the epithelial arachnoid granulations.
Neurovascular Unit
Endothelium, the site of anatomical BBB, neurons, and non-
neuronal cells (e.g., pericytes, astrocytes, and microglia) together
form a functional unit, often referred to as a neurovascular unit
(Figure 4A) (Lo et al., 2003; Iadecola, 2004; Hawkins and Davis,
2005; Zlokovic, 2005). The close proximity of different nonneuro-
nal cell types with each other and with neurons allows for effective
paracrine regulations that are critical for normal CNS functioning
and disease processes (Boille´e et al., 2006a; Deane and Zlokovic,
2007; Lok et al., 2007). These include regulation of hemodynamic
neurovascular coupling, microvascular permeability, matrix in-
teractions, neurotransmitter inactivation, neurotrophic coupling,
and angiogenic and neurogenic coupling (Figure 4B).
Vascular versus Neuronal Origin of Brain Disorders
Brain disorders may have a vascular origin (Figure 4A, arrow 1).
Vascular cells, i.e., endothelium and pericytes, can directly affect
neuronal and synaptic functions through changes in the blood
flow, the BBB permeability, nutrient supply, faulty clearance of
toxic molecules, failure of enzymatic functions, the altered secre-
tion of trophic factors and matrix molecules, abnormal expres-
sion of vascular receptors, or induction of ectoenzymes.Figure 4. Schematic of the Neurovascular Unit
(A) Endothelial cells and pericytes are separated by the basement membrane. Pericyte processes sheathe most of the outer side of the basement membrane. At
points of contact, pericytes communicate directly with endothelial cells through the synapse-like peg-socket contacts. Astrocytic endfoot processes unsheathe
the microvessel wall, which is made up of endothelial cells and pericytes. Resting microglia have a ‘‘ramified’’ shape. In cases of neuronal disorders that have
a primary vascular origin, circulating neurotoxins may cross the BBB to reach their neuronal targets, or proinflammatory signals from the vascular cells or reduced
capillary blood flow may disrupt normal synaptic transmission and trigger neuronal injury (arrow 1). Microglia recruited from the blood or within the brain and the
vessel wall can sense signals from neurons (arrow 2). Activated endothelium, microglia, and astrocytes signal back to neurons, which in most cases aggravates
the neuronal injury (arrow 3). In the case of a primary neuronal disorder, signals from neurons are sent to the vascular cells and microglia (arrow 2), which activate
the vasculo-glial unit and contributes to the progression of the disease (arrow 3).
(B) Coordinated regulation of normal neurovascular functions depends on the vascular cells (endothelium and pericytes), neurons, and astrocytes.Neuron 57, January 24, 2008 ª2008 Elsevier Inc. 185
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der (stroke), vascular dementia, hypertension, diabetes, apolipo-
protein 34 (apoE4) genotype, hyperlipidemias, homocysteinemia,
hypercoagulant blood profile, familial cerebrovascular forms of
AD (e.g, Dutch, Flemish, and Iowa Ab-precursor protein [APP]
mutations) and vascular forms of late-onset AD (Iadecola, 2004;
Zlokovic, 2005). In response to a vascular insult, signals from neu-
rons and astrocytes (Figure 4A, arrow 2) recruit microglia, which,
when activated, secrete several proinflammatory cytokines (Man
et al., 2007) (Figure 4A, arrow 3). This further aggravates the neu-
ronal injury and synaptic dysfunction. In the case of a primary
neuronal disorder (Figure 4A, arrow 2), vasculo-glial activation
follows (Figure 4A, arrow 3), and may critically modify progression
of the disease (Boille´e et al., 2006a; Lok et al., 2007).
Pericytes
Pericytes were originally discovered by Rouget in 1870 as peri-
vascular cells adjacent to capillaries. They belong to the vascular
smooth muscle cell (VSMC) lineage (Allt and Lawrenson, 2001).
Pericytes share a common basement membrane with endothe-
lial cells (Figure 4A), and have many cytoplasmic processes
that encircle capillaries. There may be up to 90 processes with
a width of 300 to 800 nm per 100 mm of capillary length, suggest-
ing that pericytes might encircle 30% to 70% of the capillary wall.
Pericyte-to-endothelia ratio in the brain is high, i.e., 1:3 com-
pared with 1:100 in striated muscles. The coverage of BEC by
pericytes varies considerably between different microvessel
types (Allt and Lawrenson, 2001).
The location of pericytes on the microvessel appears to be
functionally determined. The distance between pericytes and
BEC is estimated to be only 20 nm. Through long cytoplasmic
processes that extend along and encircle the endothelial tube,
pericytes make focal contacts with BEC through specialized
junctions (von Tell et al., 2006). At points of contact, communi-
cating gap junctions, TJ and AJ have been identified (Allt and
Lawrenson, 2001). Given such a close relationship with BEC,
and the occurrence of synapse-like peg-socket contacts, peri-
cytes are ideally suited to have many influences on brain micro-
circulation.
In the CNS, pericytes contribute to stability of microvessels
and cover a major part of the abluminal endothelial surface
(von Tell et al., 2006). In addition to providing mechanical stabil-
ity, pericytes predominantly influence vessel stability by matrix
deposition and by the releae and activation of signals that pro-
mote BEC differentiation and quiescence (Armulik et al., 2005).
The molecular mechanisms by which pericytes mediate vascular
stability are not understood. The literature is conflicting regard-
ing whether pericytes protect vessels from regression.
Perivascular pericytes release a large number of growth fac-
tors and angiogenic molecules which regulate microvascular
permeability, remodeling, and angiogenesis (Dore-Duffy and La
Manna, 2007). Several ligand-receptor systems have been impli-
cated in regulating vessel maturation and stability through inter-
actions between pericytes and BEC (von Tell et al., 2006). These
pathways involve transforming growth factor (TGF)-b and its re-
ceptor system, angiopoetins 1 and 2 and their receptor Tie2,
platelet-derived growth factor (PDGF)-B and its receptor PDGF
receptor beta (PDGF-b), and sphingosine-1-phosphate (S1P)
and its receptor S1P1. For example, endothelial-specific abla-186 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.tion of PDGF-B in mice results in mutants that survive into adult-
hood and exhibit persistent pathological changes, including
brain microhemorrhages, focal astrogliosis, and kidney glomer-
ulus abnormalities (Bjarnegard et al., 2004).
Localization studies of pericytes and BEC during angiogenesis
suggest that growing microvessels of the human telencephalon
are formed by a pericyte-driven angiogenesis (Virgintino et al.,
2007). BEC are preceded by and guided by migrating pericytes
during organization of the growing vessel wall. In vitro studies
with cultured pericytes and BEC have suggested that pericytes
strengthen the BBB permeability and maintain the vascular in-
tegrity and maturation (Nakagawa et al., 2007).
Recent studies have shown that pericytes are contractile cells
which regulate brain capillary blood flow through contraction and
relaxation (Peppiatt et al., 2006). In this regard, pericytes may
function similarly to VSMC in arterioles and small pial arteries
in the brain, which regulate CBF responses (Chow et al., 2007).
It has been speculated that pericytes and VSMC have roles in
the development of neuropathology in hypertension, diabetes,
MS, CNS tumor formation, and AD (Wyss-Coray et al., 2000;
Allt and Lawrenson, 2001; von Tell et al., 2006). Recently, it
has been shown that cerebral VSMC in AD individuals have a hy-
percontractile phenotype that leads to arterial hypercontractility
and aberrant responses to vasoactive stimuli (Chow et al., 2007).
Still, much remains to be learned about the role of pericytes in
chronic neurodegenerative disorders. This exciting field has
just begun to open up.
Basement Membrane and Matrix
The basement membrane separates BEC from its neighboring
cells, pericytes and astrocytes (Figure 4A). BEC, pericytes, and
astrocytes cooperate to generate and maintain the basement
membrane and the unique barrier properties of the BBB. The
basement membrane is composed of different extracellular ma-
trix (ECM) structural proteins (e.g., collagen and laminin). Matrix
adhesion receptors are expressed in the vascular cells, neurons,
and their supporting glial cells (i.e., microglia, oligodendroglia,
and astrocyte end-feet) (del Zoppo et al., 2006). Cells within ce-
rebral microvessels express the integrin and dystroglycan fami-
lies of matrix adhesion receptors. The functional significance of
these receptors is only now being explored.
Integrins play a key role in mediating endothelial signaling, cell
migration, and brain capillary tube formation during angiogene-
sis (del Zoppo and Milner, 2006). Matrix adhesion receptors
are essential for the maintenance of the integrity of the BBB.
Modulation of these receptors contributes to alterations in the
barrier in the disease state. Growth factors, such as VEGF, are
bound to ECM proteins and can be activated in situ by MMPs
(Zlokovic, 2006). In turn, this can regulate postischemic angio-
genic and neurogenic repair responses (Zhao et al., 2006). Sig-
nificant alterations in cellular adhesion receptors and their matrix
ligands occur during focal cerebral ischemia, MS, EAE, certain
tumors of the CNS, and arteriovenous malformations, which
support their functional significance in the normal state.
Astrocytes
Astrocytes are positioned between neurons, pericytes, and cap-
illary BEC, and communicate with these cells via their numerous
‘‘foot processes’’ (Figure 4A). Astrocyte-BEC interactions have
a major role in regulating brain water and electrolyte metabolism
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Astrocytes contribute to brain communication pathways by mod-
ulating synaptic transmission (Newman, 2003) and neuronal firing
thresholds and plasticity (Nedergaard et al., 2003). In the subforn-
ical organ, astrocytes act as a ‘‘salt sensor,’’ and, using lactate as
a signal, control local activity of neurons involved in neural,
hormonal, and behavioral responses underlying sodium homeo-
stasis (Shimizu et al., 2007).
VSMC in small arteries (Iadecola, 2004) and astrocytes con-
tribute to neurovascular coupling, which synchronizes neuronal
metabolic demands to local CBF regulation (Anderson and Ne-
dergaard, 2003). In brain slices, astrocytes detect glutamate-de-
pendent synaptic activity, which causes vasodilation by a mech-
anism that involves prostanoids (Zonta et al., 2003). In vivo,
photolysis of caged Ca2+ in astrocytic endfeet in the somatosen-
sory cortex of mice results in an increase in CBF (Takano et al.,
2006). Abnormal astrocytic activity coupled to vascular instabil-
ity has been observed in AD models (Takano et al., 2007).
Early studies with EM markers injected into the CSF demon-
strated that astrocytes did not structurally contribute to the
BBB (Brightman and Reese, 1969). However, the src-suppressed
C-kinase substrate (SSeCKS) in astrocytes is responsible for the
decreased expression of VEGF and increased release of the anti-
permeability factor angiopotein-1 (Lee et al., 2003). It has been
suggested that SSeCKS overexpression can increase the ex-
pression of the TJ molecules and decrease paracellular perme-
ability in endothelial cells, suggesting that astrocytes may regu-
late the microvascular permeability. However, conflicting data
have been reported regarding possible roles of astrocytes in con-
trolling BBB differentiation and permeability. More studies are
needed to clarify these issues.
Microglia
Microglia were first described in 1932 by del Rio-Hortega as
a distinct class of glial cells. Microglia play critical roles in innate
and adaptive immune responses of the CNS. Microglia are de-
rived from leptomeningeal mesenchymal cells, which enter the
brain and transform into microglia (Bechmann et al., 2007). The
process involves (1) passage across the postcapillary venules
into the Virchow-Robin spaces, and (2) subsequent progression
across the glia limitans into the neuropil. This second step in-
volves perivascular antigen recognition and the induction of
MMPs. Circulating monocytes provide another important source
of microglia in the brain (Bechmann et al., 2005). The infiltration of
blood-derived monocytic cells and their morphologic transfor-
mation into microglia in zones of acute, anterograde (Wallerian)
axonal degeneration have been demonstrated.
In the absence of pathology, the ‘‘resting’’ microglia are cells
with small bodies and long, thin processes. Brain pathology is
associated with activation of microglia. Activated microglia
lose the long extensions typical of the resting microglia, and
show stubby processes. During activation, microglia transform
from ‘‘ramified’’ to an ‘‘ameboid’’ form, and finally to a phagocytic
form. This evolution is associated with changes in surface anti-
gen expression and cytokine release.
Studies with rat bone marrow chimeras have demonstrated
that a subset of endogenous CNS cells, commonly termed ‘‘peri-
vascular microglial cells,’’ is bone marrow derived (Hickey and
Kimura, 1988). These perivascular cells are fully competent topresent antigens to lymphocytes in an appropriately restricted
manner. Trafficking signals that guide the transmigration of leu-
kocytes into the brain, as well as leukocyte migratory routes,
have been well defined (Man et al., 2007). The connection of mi-
croglia in the brain with circulating monocytes and bone marrow
cells has changed our concept of the brain as an immune privi-
leged site that separates central microglia from its peripheral
precursor pool.
In addition to being involved in MS, mononuclear phagocytes
from blood are also recruited in other neurodegenerative dis-
eases, such as AD, via transport across the BBB. Chemokines
in the brain can recruit immune cells from the blood or from within
the brain (Britschgi and Wyss-Coray, 2007). Disrupting this line of
communication exacerbates the disease process in a mouse
model of AD, as shown in AD mice deficient in Ccr2, a chemokine
receptor on microglia that normally mediates the accumulation
of mononuclear phagocytes at sites of inflammation, but is linked
to more rapid disease progression when absent (El Khoury
et al., 2007).
Angiogenesis and Neurogenesis
The mechanisms involved in wiring the neural and vascular net-
works share many similarities (Carmeliet and Tessier-Lavigne,
2005). These include shared growth factors and receptors, sim-
ilar signaling cues for new cell formation and migration, and
shared physical space, as a result of parallel anatomic patterning
and development. For example, VEGF and its receptor VEGR2
regulate axonal growth, neuronal survival, and new vessel forma-
tion (Greenberg and Jin, 2005). Neuropilin receptor (Nrp1) binds
VEGF 164/5 on vascular cells and is a coreceptor for the axon
guidance molecule semaphorin 3A. Fibroblast growth factor-2
(FGF-2), TGF-b, and PDGF are angiogenic factors that induce
proliferation of neural precursors. The four major families of neu-
ronal guidance cues, ephrins, semaphorins, slits, and netrins, di-
rect patterning of the vascular system.
In the adult brain, there are several discrete foci of persistent
angiogenesis (Greenberg and Jin, 2005). Angiogenesis is tightly
coupled to neurogenesis in the adult mammalian brain (Palmer
et al., 2000) and the avian brain (Louissaint et al., 2002). Gonadal
steroid-mediated induction of VEGF in higher vocal control (HVC)
nucleus in the adult avian brain occurs concurrently with VEGFR2
expression in HVC endothelial cells (Louissaint et al., 2002). This
leads to sprouting angiogenesis and release of brain-derived
nerve growth factor (BDNF) from steroid-stimulated HVC endo-
thelium, which, in turn, recruits neurons in the adult HVC.
The major progenitor pools of the adult human brain include
ventricular zone neuronal progenitor cells, hippocampal neuronal
progenitors, and parenchymal glial progenitor cells (Goldman,
2007). Newly generated cells in the adult mouse hippocampus
have neuronal morphology, membrane properties, action poten-
tials, and functional synaptic inputs similar to those found in ma-
ture dentate granule cells (van Praag et al., 2002). New neurons,
similar to mature granule neurons, form contacts by axosomatic,
axodendritic, and axospinous synapses (Toni et al., 2007). New
dendritic spines primarily synapse on multiple-synapse boutons,
suggesting that initial contacts are preferentially made with pre-
existing boutons already involved in a synapse.
In sprouting angiogenesis, specialized endothelial tip cells
lead the outgrowth of blood-vessel sprouts toward gradients ofNeuron 57, January 24, 2008 ª2008 Elsevier Inc. 187
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that inhibition of Notch signaling with g-secretase inhibitors or
genetic inactivation of Notch ligand delta-like 4 (Dll4) signaling
promotes increased numbers of tip cells, which control vessel
sprouting in the mouse retina (Hellstrom et al., 2007). This work
has suggested that modulators of Dll4 or Notch signaling, as
for example g-secretase inhibitors developed for AD, might be
used as pharmacological regulators of angiogenesis.
The importance of angiogenesis and neurogenesis in brain re-
modeling after an acute ischemic insult is well recognized (Zhang
et al., 2007). Yet the prevailing concept states that the aging
brain affected by a chronic neurodegenerative process has rela-
tively modest regenerative capability. Whether brain repair can
be enhanced by new therapeutic approaches remains to be
addressed by future studies.
Neurovascular Uncoupling in the Aging Brain
Brain varies its blood flow according to local tissue metabolic
demands. An adequate blood supply is ensured by a tight cou-
pling between neural activity and blood flow. The link between
regional synaptic activity and regional CBF, termed functional
hyperemia, is the basis for functional MRI, which has revolution-
ized our understanding of human brain in health and disease
(Drake and Iadecola, 2007). Reductions in resting CBF or altered
responses to brain activation may occur in different CNS regions
in AD, PD, MS, and other CNS disorders (Lo et al., 2003; Iade-
cola, 2004; Drake and Iadecola, 2007; Lok et al., 2007).
Modest, 20% reductions in CBF, as seen in the aging brain, are
associated with diminished cerebral protein synthesis (Hoss-
mann, 1994). More severe regional reductions in CBF, as seen
in chronic neurodegenerative disorders, lead to shifts in intracel-
lular pH and water, and accumulation of glutamate and lactate in
brain ISF (Drake and Iadecola, 2007). CBF reductions greater than
50% impair ATP synthesis and decrease the ability of neurons to
fire action potentials. Finally, severe reductions in CBF (>80%),
similar to those found in ischemic stroke, lead to electrolyte dys-
balance and ischemic neuronal death. Changes in the brain cap-
illary unit, degeneration of brain capillaries, reductions in resting
CBF, or a combination thereof maybe the first signs of the disease
process prior to neuronal changes and neurodegeneration.
Alzheimer’s Disease
AD is characterized by a progressive cognitive decline associ-
ated with neurovascular dysfunction (Iadecola, 2004; Zlokovic,
2005), accumulation of neurotoxic Ab on blood vessels and in
the brain parenchyma (Rovelet-Lecrux et al., 2006; Hardy,
2006; Deane and Zlokovic, 2007), and intraneuronal lesions, or
neurofibrillar tangles (Lee et al., 1991; Santacruz et al., 2005;
Tanzi, 2005). Ab plays a central role in the development of AD
pathology (Snyder et al., 2005; Tanzi, 2005; Hardy, 2006; Rove-
let-Lecrux et al., 2006; Selkoe, 2001; Deane and Zlokovic, 2007;
Haass and Selkoe, 2007). Brain Ab is elevated in patients with
sporadic AD and inherited FAD. Increased Ab42 levels in the
brain ISF result in the formation of neurotoxic Ab oligomers
(Haass and Selkoe, 2007). Neurovascular accumulation of Ab
and vascular deposition of amyloid result in the development
of cerebral amyloid angiopathy (CAA) (Ghiso and Frangione,
2002; Greenberg et al., 2004).188 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.Most AD cases (99%) present with the late onset, i.e., in
individuals over 65 years of age, without evidence of Mendelian
genetic transmission (Tanzi and Bertram, 2005). Late-onset AD
individuals typically do not have increased production of Ab. Ac-
cording to current concepts, Ab accumulates in the brain in AD
likely due to its faulty clearance from the brain (Zlokovic et al.,
2000b; Selkoe, 2001; Tanzi et al., 2004; Holtzman and Zlokovic,
2007). In mouse models of AD, including APP-overexpressing
APPsw+/ mice and transgenic APP mice harboring vasculo-
tropic Dutch and Iowa mutations, dense plaques develop initially
on blood vessels or as a classical CAA (Deane et al., 2004a; Ku-
mar-Singh et al., 2005). It is believed that plaques are generated
on blood vessels due to deficient Ab clearance across the BBB
or along Virhoff-Robin arterial spaces in the brain.
Microvascular Pathology
Reduced microvascular density, an increased number of frag-
mented vessels with fewer intact branches, atrophic string ves-
sels, increased irregularity of capillary surfaces, marked changes
in the vessel diameter, capillary basement membrane thicken-
ing, and collagen accumulation in the basement membrane
have been described in AD (Farkas and Luiten, 2001; Bailey
et al., 2004).
BBB Influx of Ab
RAGE is a major influx transporter for Ab across the BBB (Deane
et al., 2003). In AD and transgenic models of b-amyloidosis,
RAGE expression increases in the affected cerebral vessels,
microglia, and neurons (Yan et al., 1996; Deane et al., 2003; Do-
nahue et al., 2006). RAGE binds to different forms of Ab and me-
diates its pathophysiologic cellular responses. Under physiolog-
ical conditions, RAGE is expressed at relatively low levels at the
BBB, except at the endothelium of larger brain microvessels.
However, the accumulation of RAGE ligands (e.g., AGE proteins
and Ab) in the aging brain increases cerebrovascular RAGE ex-
pression. It has been shown that Ab/RAGE interaction at the lu-
minal membrane of the BBB (Figure 5A) results in (1) transcytosis
of circulating Ab across the BBB into the brain parenchyma and
its binding to neurons; (2) NF-kB-mediated endothelial activation
resulting in secretion of proinflammatory cytokines (e.g., tumor
necrosis factor-a and interleukin-6), the expression of adhesion
molecules (e.g., ICAM-1 and VCAM); and (3) generation of endo-
thelin-1, which suppresses CBF. These cellular events may be
implicated in disease onset and progression in AD models, and
possibly in AD.
Ab/RAGE interaction contributes to the neuronal killing directly
by producing oxidative damage to RAGE-expressing neurons,
and indirectly, by activating microglia (Yan et al., 1996). Inhibition
of Ab/RAGE interaction in the affected vasculature inhibits cyto-
kine production, oxidant stress, and Ab BBB transport (Deane
et al., 2003). Thus, RAGE is an important therapeutic target in
AD. The inhibitors of Ab/RAGE interaction have been shown to
stabilize the BBB functions, reduce neuroinflammation, and
improve the resting CBF and the CBF responses to brain activa-
tion. Some RAGE/Ab blockers are currently being tested in AD
patients.
Recent work has confirmed that blood is a major, chronic
source of soluble Ab peptides in the brain (Clifford et al., 2007).
In rats, Ab peptides cross a defective BBB by passive diffusion
followed by selective binding to certain subtypes of neurons.
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tients with MRI-evidenced brain atrophy do not correlate with
CSF-to-plasma Ab40 and Ab42 ratios (Matsumoto et al., 2007),
suggesting that diffusion is not a key factor regulating Ab in the
CNS. Earlier studies in guinea pigs have demonstrated that
plasma-derived Ab40 and Ab42 cross the intact BBB at slow
rates by sharing a common transport system (Martel et al.,
1996a). Subsequent work in AD mice has identified that RAGE
is a shared influx transporter for Ab peptides at the BBB (Deane
et al., 2003). Therefore, specific influx and efflux transport mech-
anisms for Ab play a key role in regulating brain Ab (Deane and
Zlokovic, 2007).
In addition to RAGE, apolipoprotein J (apoJ) can facilitate
transport of plasma-derived Ab across the BBB (Zlokovic,
1996). In contrast, circulating apoE2 and apoE3, but not apoE4,
block transport of plasma Ab into the brain (Martel et al., 1997).
Transport of Ab-apoJ complexes across the BBB is mediated
via gp330/megalin or low-density lipoprotein receptor related
protein 2 (LRP2) (Zlokovic et al., 1996). The role of LRP2 in trans-
port of Ab is still not completely understood because LRP2 is sat-
urated by apoJ at physiological plasma levels (Shayo et al., 1997).
In addition, apoJ is not a major transport protein for Ab in humanplasma (Sagare et al., 2007). Whether apoJ/LRP2-mediated
transport of Ab in the CNS has a role in disease progression
and development of Ab pathology in AD has not been explored.
BBB Clearance of Ab
Low-density lipoprotein receptor related protein 1 (LRP1) is a ma-
jor efflux transporter for Ab across the BBB (Shibata et al., 2000).
LRP1 is a member of the LDL receptor family and acts as a mul-
tifunctional scavenger and signaling receptor. Binding of Ab to
LRP1 at the abluminal side of the BBB initiates Ab clearance
from brain to blood via transcytosis across the BBB (Figure 5A)
(Shibata et al., 2000; Deane et al., 2004a; Cirrito et al., 2005;
Bell et al., 2007). In the liver, LRP1 mediates Ab systemic clear-
ance (Tamaki et al., 2006).
b-secretase cleaves the N terminus extracellular domain of
LRP1 (von Arnim et al., 2005), which releases soluble LRP1
(sLRP1) in plasma. In humans, sLRP1 normally binds 70%–
90% of Ab in plasma (Sagare et al., 2007). It has been shown
that binding of Ab to sLRP1 is compromised in AD, which in
turn may contribute to elevated Ab levels in the brain. Recombi-
nant LRP1 clusters, such as cluster IV (LRP-IV), can effectively
sequester Ab in AD plasma and APPsw+/ mice, resulting in Ab
efflux from the mouse brain (Sagare et al., 2007). Thus, LRP-IVFigure 5. The Role of the BBB in the Pathogenesis of Alzheimer’s Disease, or AD
(A) Transport equilibrium for amyloid b-peptide, or Ab. The cell-surface LRP1 on the abluminal membrane binds different forms of Ab (e.g., monomers, oligomers,
and aggregates) and initiates Ab transcytosis across the BBB followed by its export into the circulation. In the case of Ab overload, LRP1 loses its normal protein
conformation and undergoes the accelerated proteosomal degradation. Ab efflux is influenced by its transport binding proteins in the brain, e.g., apoE and apoJ,
or a2-macroglobulin. b-secretase (BACE) cleaves the N terminus extracellular domain of LRP1, which generates the soluble form of LRP1 (sLRP1). In human
plasma, >70% of Ab is normally bound to sLRP1. Native plasma sLRP1 is a major endogenenous peripheral ‘‘sink’’ agent for Ab. The remaining Ab in the plasma
is bound to other Ab transporting proteins (e.g., apoJ). A small fraction of plasma Ab is free. On the luminal membrane, free Ab that escapes the sLRP1 surveillance
in the blood interacts with the receptor for advanced glycation end products (RAGE). Ab/RAGE interaction mediates transport of Ab from blood to brain, and
activates the endothelium through reactive oxygen species (ROS)-induced nuclear translocation of NF-kB. This triggers secretion of proinflammatory cytokines
(e.g., interleukin-6 [IL-6] and tumor necrosis factor-a [TNF-a]), the expression of adhesion molecules at the BBB (e.g., ICAM1 and VCAM), and secretion of en-
dothelin-1, a suppressor of the blood flow.
(B) The role of vascular genes. In AD, low levels of expression of the mesenchyme homeobox gene 2 (MEOX-2) in the brain endothelium inhibit vascular endothelial
growth factor (VEGF)-mediated angiogenesis, resulting in a premature apoptotic cell death, brain capillary regression, and reduced LRP1 expression. These
events lead to both Ab accumulation in the brain and brain hypoperfison. RAGE amplifies this pathogenic cascade. In small cerebral arteries, overexpression
of serum response factor (SRF) and myocardin (MYOCD), the two transcription factors that orchestrate the vascular smooth muscle cell (VSMC) phenotype, leads
to a hypercontractile VSMC phenotype overexpressing several SRF/MYOCD-regulated contractile proteins and the SRF-dependent genes that regulate Ca2+
homeostasis. These events reduce resting blood flow and suppress brain-activation-controlled blood flow responses. The BBB compromise and a neuroinflam-
matory response both aggravate synaptic and neuronal dysfunction, resulting in neuronal loss and dementia.Neuron 57, January 24, 2008 ª2008 Elsevier Inc. 189
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Ab clearance agents or sLRP replacement therapy for AD with an
enhanced peripheral ‘‘sink’’ action for Ab.
Reduced expression of LRP1 has been reported during normal
aging in rodents and nonhuman primates, and in AD individuals
associated with positive staining of cerebral vessels for Ab40
and Ab42 (Shibata et al., 2000; Deane et al., 2004a; Donahue
et al., 2006). Mice with severe functional deficiency in LRP1 at
the BBB develop accumulations of Ab when crossed with APP-
overexpressing mice (Van Uden et al., 2002). However, the over-
expression of LRP-IV minigene on neurons promotes Ab reten-
tion in the CNS, suggesting that LRP1 on neurons mediates
retention of Ab in the brain (Zerbinatti et al., 2004). In contrast,
LRP1 or another lipoprotein receptor on astrocytes mediates
degradation of amyloid deposits via apoE (Koistinaho et al.,
2004). Therefore, different cells of the vasculo-glial unit may act
together to eliminate Ab. Binding of Ab to apoJ, apoE, and
a2-macroglobulin critically alters Ab clearance rates from the
brain (Figure 5A) and can influence its vascular and parenchymal
accumulation (Holtzman and Zlokovic, 2007; Bell et al., 2007).
Mice that lack P-gp at the BBB (knockouts for mdr1a and
mdr1b genes) have reduced clearance of Ab from the CNS and
lower levels of LRP1 in brain capillaries (Cirrito et al., 2005). Cross-
ingmdr1a/mdr1bnull mice with APP-overexpressing mice accel-
erates accumulation of Ab and amyloid deposition, raising a pos-
sibility that mdr1a and mdr1b genes may influence Ab clearance
either directly through P-gp or indirectly through LRP1.
In addition to receptor-mediated transport, free diffusion of Ab
via the ISF-CSF bulk flow contributes to Ab removal from the
CNS (Silverberg et al., 2003). The exact contribution of this path-
way to overall Ab clearance is not known. It has been estimated
that the diffusional component of Ab clearance might eliminate
up to 10%–15% of Ab in mice (Shibata et al., 2000).
Aberrant Angiogenesis
Recent findings suggest that degeneration of the BEC in AD and
AD models may reflect an aberrant angiogenesis. AD BEC ex-
press extremely low levels of the mesenchyme homebox gene
2 (MEOX-2), a transcription factor which normally regulates vas-
cular cell differentiation and remodeling, and whose expression
in the adult brain is restricted to the vascular system. Low levels
of MEOX-2 expression mediate abnormal angiogenic responses
of AD BEC to VEGF and other angiogenic factors (Wu et al.,
2005), resulting in premature vessel regression, reduced resting
CBF, and improper formation of the BBB (Figure 5B). Low levels
of MEOX-2 promote proteasomal degradation of LRP1, which
lowers the Ab clearing capability at the BBB, which in turn poten-
tially leads to Ab accumulation on the blood vessels. It has been
shown that Ab accumulations on the outer membrane of the
blood vessels are anti-angiogenic, and therefore might contrib-
ute to the observed reductions in the brain capillary density in
AD models and AD (Paris et al., 2004a, 2004b). Aberrant angio-
genesis may have an amyloidogenic effect in the brain due to
compromised BBB clearance of Ab (Deane et al., 2004b).
Arterial Component
Ab is a potent vasoconstrictor in cerebral circulation (Thomas
et al., 1996). In APP-expressing mice, impaired endothelium-
dependent regulation of neocortical microcirculation (Iadecola
et al., 1999) and reductions in functional hyperemia (Niwa190 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.et al., 2000) have been observed at an early stage. A mismatch
between CBF, metabolism, and brain activity has been shown
in sporadic AD (Smith et al., 1999; Bookheimer et al., 2000; Rui-
tenberg et al., 2005; Drake and Iadecola, 2007).
Pial and intracerebral arteries in AD are affected by CAA. The
VSMC layer is often reduced, resulting in the rupture of the vessel
wall and intracerebral bleeding (Ghiso and Frangione, 2002;
Greenberg et al., 2004). Pathogenic levels of vasculotropic mu-
tant forms of Ab (e.g., Dutch, Iowa, Arctic, Flemish, and Italian)
accelerate VSMC degeneration, contributing to hemorrhagic
strokes, as in familial forms of AD.
Recent studies have demonstrated that the expression of two
transcription factors that control VSMC cell differentiation,
namely serum response factor (SRF) and myocradin (MYOCD),
is increased in AD, resulting in a hypercontractile arterial pheno-
type, brain hypoperfusion, and diminished functional hyperemia
(Chow et al., 2007) (Figure 5B). These events may contribute to
hypoperfusion observed in AD brains.
Large cerebral arteries do not develop CAA. But in AD, they are
frequently affected by atherosclerosis (Casserly and Topol, 2004;
Beach et al., 2007). Atherosclerosis reduces brain perfusion and
may precipitate a chronic ischemic condition in AD. The Rotter-
dam Scan Study demonstrated that silent brain infarcts detected
with MRI are associated with dementia in elderly people (Vermeer
et al., 2003). The nun study found that demented AD individuals
with amyloid and tau pathology have numerous brain microin-
farctions (Snowdon et al., 1997). It has been suggested that cere-
brovascular disease and brain infarction may contribute to the
severity of cognitive decline in AD (Song et al., 2007b; Sheng
et al., 2007). However, the exact pathways by which atheroscle-
rosis and arteriolosclerosis contribute to cognitive decline, and
the relationship between vascular brain damage and white matter
hyperintensities on MRI and cognitive decline, are still not com-
pletely understood (Chui et al., 2006).
The link between ischemia and increased Ab production (Iade-
cola, 2004), on one hand, and the accumulation of hyperphos-
phorylated tau in cortical neurons and filament formation similar
to that present in human neurodegenerative tauopathies and AD
(Gordon-Krajcer et al., 2007; Wen et al., 2007), on the other hand,
have been reported in rodent models of stroke. Thus, brain hypo-
perfusion may create, at least in animal models, AD-like patho-
logical changes in the brain.
Vascular Factors
Vascular risk factors might be responsible for cognitive decline in
the elderly according to several epidemiologic studies, including
the largest population-based Rotterdam study (Hofman et al.,
1997; Ruitenberg et al., 2005). A number of risk factors for AD
and vascular dementia overlap, including old age, atherosclero-
sis, stroke, homocysteine, hypertension, hyperlipidemia, head
injury, transient ischemic attacks, high serum viscosity, throm-
bogenic factors, cardiac disease, apoE4 (Iadecola, 2004; Zlo-
kovic, 2005; de la Torre, 2006), and diabetes (Luchsinger et al.,
2007). Brains of AD patients are typically hypoperfused and hyp-
oxic compared with those of normal subjects. Notably, hypoxia
downregulates MEOX-2 in the brain endothelium (Wu et al.,
2005) and stabilizes the expression of MYOCD and SRF in the
VSMC in small cerebral arteries (Chow et al., 2007). It is possible
that hypoxia might be upstream of the gene expression changes
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rovascular unit in AD. More work is needed to clarify the exact re-
lationship between hypoxia and the vascularly restricted genes
in the pathogenesis of AD.
Neurovascular Disease Pathway
A number of models have been proposed to explain the disease
pathway or pathways in AD. The limited scope of this review pre-
cludes me from comparing and discussing all existing models
and theories of AD and including several important clinical ob-
servations linking cerebrovascular disease and AD, and cerebro-
vascular disease and cognitive decline. Instead, I will briefly
summarize major findings that have been discussed in greater
detail in earlier sections, and focus on the neurovascular cas-
cade in AD.
According to the proposed model (Figure 5B), changes in the
expression of key vascular genes and receptors in brain capillar-
ies and small cerebral arteries may compromise (directly or indi-
rectly) several BBB functions. This in turn leads to reductions in
the resting CBF and attenuated CBF responses to brain activa-
tion, accumulation of Ab, and a neuroinflammatory response, re-
sulting in BBB breakdown. In an early phase, faulty clearance of
Ab at the BBB may favor accumulation of neurotoxic Ab oligo-
mers in the brain ISF. Ab oligomers and focal reductions in the
capillary blood flow can affect synaptic transmission, cause
the neuronal injury, and initiate recruitment of microglia from
the blood or within the brain (Figure 6A). At an early symptomatic
stage, the BBB starts losing properties of an Ab clearing mem-
brane, and the activated endothelium secretes proinflammatory
cytokines and CBF suppressors. This results in more pro-
nounced synaptic dysfunction, accumulation of intraneuronal
tangles, and activation of microglia. At a late symptomatic stage,
the capillary unit is distorted with the degenerated endothelial
barrier. There is a severe loss of Ab clearing capability, resultingin amyloid formation on the outer side of the capillary membrane,
an increased number of neurofibrillary tangles, and an increased
number of activated microglia and astrocytes. At the final stage,
the capillary unit disappears under the amyloid deposits contem-
poraneous with synaptic and neuronal loss.
Parkinson’s Disease
PD is a chronic, progressive neurodegenerative movement disor-
der. Tremors, rigidity, slow movement (bradykinesia), poor bal-
ance, and difficulty walking (parkinsonian gait) are primary symp-
toms. PD results from the degeneration of dopamine-producing
nerve cells in the brain, specifically in the substantia nigra and
the locus coeruleus, although an initial locus in the dorsal motor
nucleus of the vagus nerve (in the medulla) has also been sug-
gested (Braak et al., 2006). When dopamine production is de-
pleted, the motor system nerves are unable to control movement
and coordination. PD individuals have typically lost over 80% of
their dopamine-producing cells by the time symptoms appear.
BBB Transport
Dopamine restorative therapy with its precursor L-DOPA has
provided symptomatic benefit to PD patients. The effectivenes
of L-DOPA is a perfect example of how the BBB transport
systems can be utilized to deliver neurotherapeutics. Namely,
L-DOPA, but not dopamine, is transported across the BBB in hu-
mans via the L1 facilitative transporter (Hawkins et al., 2006). Af-
ter transport across the BBB, L-DOPA is converted to dopamine,
likely at the surviving dopaminergic terminals and at serotonergic
and adrenergic nerve terminals that contain decarboxylase.
It has been suggested that absorption or metabolism of puta-
tive PD toxins, and their faulty elimination across the BBB, may
play a role in the pathogenesis of PD. Low activity of P-gp efflux
transporter at the BBB in the midbrain of individuals at risk for PD
has been proposed as a mechanism mediating the retention ofFigure 6. Schematic of the Involvement of the Neurovascular Unit in the Pathogenesis of AD
Early phase. Brain hypoperfusion and impaired BBB clearance of Ab lead to accumulation of neurotoxic Ab oligomers in the brain. Reduced blood flow and ac-
cumulated Ab oligomers can both initiate the neuronal injury. Early symptomatic.More pronounced reductions in the blood flow, activation of the endothelium and
pericytes, a loss of BBB Ab clearance properties, an increasing accumulation of Ab in the brain, and activation of microglia and astrocytes create a chronic prob-
lem for normal synaptic transmission and neuronal function. Neurofibrillary tangles may accumulate in neurons in response to both ischemic injury and Ab. Late
symptomatic. Degeneration of the endothelial cell wall and pericytes precludes clearance of Ab and eliminates the blood flow from the capillary unit, resulting in
accumulation of metabolic waste products, changes in the pH, and electrolyte unbalance. These chemical changes in the brain microenvironment present an
insurmountable challenge for synaptic and neuronal function. Amyloid accumulates on the vessel wall. There is also a more prominent accumulation of the intra-
neuronal tangles. End stage. This stage is characterized by a profound neuroinflammatory response and a collapse of the capillary unit, accompanied with a loss
of axonal-dendritic synapses and neurons, which disappear under the amyloid deposits.Neuron 57, January 24, 2008 ª2008 Elsevier Inc. 191
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in PD pathogenesis has been demonstrated by verapamil (a
P-gp substrate) retention on PET scans of the midbrain,
but not of other brain regions, in PD individuals (Kortekaas
et al., 2005).
The importance of P-gp in the pathogenesis of PD has been
also suggested by the MDR1 gene polymorphism studies in Chi-
nese populations (Lee et al., 2004). These studies have demon-
strated that some polymorphisms in theMDR1 gene may be pro-
tective and reduce the risk of PD. Other studies have suggested
that mutation in theMDR1 gene may predispose carriers to dam-
aging effects of pesticides, leading to a PD phenotype (Droz´dzik
et al., 2003).
Studies with paraquat, an insecticide frequently used to pro-
duce parkinsonism in rodents, have demonstrated that its trans-
port across the BBB can be blocked by competitive inhibition of
the BBB L1 AA transporter (McCormack and Di Monte, 2003).
This suggests that the L1 AA transporter may be involved in
mediating the entry of parquat in the brain. Interestingly, some
species, like guinea pigs, may exhibit selective regional transport
of dopamine across the BBB in the caudate-putamen, but not in
other brain regions (Martel et al., 1996b). This, however, has not
been found in other species, including humans.
In a hemiparkinsonian rat model, L-DOPA therapy increases
endothelial proliferation and its own transport into the basal gan-
glia, subventricular zone, and hippocampal dentate gyrus (Westin
et al., 2006). It has been suggested that these changes correlate
with the development of dyskinesia, a side effect of L-DOPA.
Circumventing the BBB
Glial-derived neurotrophic factor (GDNF) can regenerate dam-
aged dopaminergic nerve terminals in animal models of PD, but
does not cross the BBB. In a recent clinical trial, GDNF was ad-
ministered directly into the putamen, which enhanced dopami-
nergic function in the immediate vicinity of the catheter tip, but
generated no clinical improvement (Lang et al., 2006). In general,
clinical trials with neurotrophic factors, gene therapy, or peptide
neurotheraputics face a major challenge in how to circumvent the
BBB (Pardridge, 2007).
Microvascular Changes
Early studies have demonstrated that melanin-containing neu-
rons of the zona compacta have a very close spatial relationship
with the blood supply (Issidorides, 1971). The neuronal vascular
contact is so intimate that the capillary appears to have an al-
most intracellular position. In PD individuals, normal contacts
between nigral neurons and capillaries are lost at an early dis-
ease stage, and capillaries do not maintain their normal shape.
Capillary basement membrane thickening and collagen accumu-
lation have also been shown in PD (Farkas et al., 2000).
Neuroinflammation
Neuroinflammation appears to be a ubiquitous finding in PD pa-
tients and experimental models of PD. Phagocyte activation, in-
creased synthesis and release of proinflammatory cytokines,
complement activation, activation of microglia, and release of re-
activeoxygenspecies (ROS) havebeendescribed (Whitton,2007).
CBF Dysregulation
Orthostatic hypotension is one of the many autonomic distur-
bances observed in PD. Normally brain perfusion does not
depend on systemic blood pressure, a mechanism known as192 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.cerebral autoregulation. Impaired autoregulation of brain perfu-
sion, independent of dopaminergic treatment, has been demon-
strated in PD patients subjected to a drop in blood pressure
compared with controls (Vokatch et al., 2007).
Amyotrophic Lateral Sclerosis
ALS is a chronic neurodegenerative disorder of motor neurons in
the brain, brainstem, and spinal cord that results in a progressive
paralysis that kills individuals within 3 to 5 years of onset (Boille´e
et al., 2006a). About 10% of patients have a familial history,
whereas 90% of cases are sporadic. Mutations in superoxide
dismutase-1 (SOD1) are the most common form of inherited
ALS, accounting for almost 25% of familial cases.
Neurovascular Unit
The current model of ALS disease suggests that toxicity derived
from microglia and astrocytes contributes to disease progression
and motor neuron degeneration (Boille´e et al., 2006a, 2006b;
Beers et al., 2006; Di Giorgio et al., 2007; Nagai et al., 2007).
Blood Vessels
The role of blood vessels in the pathogenesis of ALS is not clear.
Human data suggest that two angiogenic factors, i.e., VEGF
(Lambrechts et al., 2003) and angiogenin (Greenway et al.,
2006), might have a role in ALS. Mice with a mutation that elim-
inates hypoxia-responsive induction of the Vegf gene (Vegfad/d)
develop late-onset motor neuron degeneration (Oosthuyse
et al., 2001). It has been reported that treatment of SOD1G93A
rats with intracerebroventricular VEGF (Storkebaum et al.,
2005), or of SOD1G93A mice with a VEGF-expressing lentiviral
vector that is transported retrogradely to motor neurons (Azzouz
et al., 2004), reduces pathology and extends survival.
BBB Breakdown
Earlier studies in ALS patients have suggested a possible blood-
CSF barrier and BBB breakdown by demonstrating increased
levels of albumin, IgG, and complement components in the
CSF or in the spinal cord (Engelhardt and Appel, 1990; Meucci
et al., 1993). More recent studies that focused on the axonal dam-
age markers in the CSF (e.g., tau and neurofilaments) reported
a mild increase in the CSF-to-serum albumin ratio in 28% of
ALS patients (Brettschneider et al., 2006). Leakages into the spi-
nal cord of serum plasma proteins (i.e., Ig) and deposition of red-
blood-cell-derived neurotoxic products such as hemoglobin
have been shown in SOD1G93A mutant mice at the onset of the
disease (Z. Zhong and B.V. Zlokovic, unpublished data). Figure 7
illustrates the Zlokovic-Cleveland model for the possible role of
BBB breakdown in the pathogenesis of ALS. Based on this
model, BBB breakdown resulting in a leakage of serum proteins
may generate edema with focal hypoxic conditions in the spinal
cord tissue. In addition, leakage of Igs that interact with motor
neuron antigens can produce ROS (Wentworth et al., 2000) and
initiate an autoimmune response, which in turn can cause demy-
elination, disruption of neuronal transmission, and cell death.
Hemoglobin released from extravasated red blood cells confers
direct toxicity to neurons (Regan and Guo, 1998), which is asso-
ciated with ROS production, lipid peroxidation, and neuronal cell
death.
More studies are needed, however, to clarify when and how
the BBB breakdown contributes to motor neuron injury in exper-
imental models of ALS. For example, it is not clear whether BBB
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flammatory response. The future studies should also elucidate
whether BBB breakdown is a common ramification of all SOD1
mutations with different biochemical characteristics.
Blood Flow
It has been shown that the spinal cord ischemia worsens motor
neuron degeneration and functional outcome in Vegfad/d mice,
while similarly, the absence of hypoxic induction of VEGF in
mice that develop motor neuron disease from expression of
ALS-linked mutant SOD1G93A yields substantially reduced sur-
vival (Lambrechts et al., 2003). Although these studies have sug-
gested that hypoxia may play a role in inducing motor neuron
disorder, the contribution of the spinal cord hypoperfusion to
the development of ALS pathology still remains unclear.
Multiple Sclerosis
MS damages the myelin sheaths that surround and protect nerve
cells in the brain and spinal cord. The symptoms of the disease
may vary and can include visual disturbances, muscle weakness,
trouble with coordination and balance, sensations such as numb-
ness or prickling, and thinking and memory problems. MS begins
between the ages of 20 and 40 and affects women more than
men. Currently, there is no cure for MS, although some therapeu-
tics may slow down the disease progression and help control
symptoms.
The cause of MS is unknown. The current view is that MS is an
autoimmune disease. Early studies have considered the CNS as
an immunologically privileged site. However, today a body of ev-
idence suggests that immune reactions take place in the CNS
with distinctive features that are dictated in part by specific
CNS anatomy; this includes the lack of endogenous antigen-
presenting cells, lack of the lymphatic system, and the presence
Figure 7. Schematic of the BBB Involvement in the Pathogenesis of
Amyotrophic Lateral Sclerosis, or ALS: Zlokovic-Cleveland Model
Focal BBB breakdown with edema and serum protein leakage (e.g., albumin
and Igs) results in focal tissue hypoxia. Red blood cell (RBC) extravasation re-
sults in release of neurotoxic hemoglobin (Hb)-derived products focally in the
spinal cord tissue. Free Hb is directly toxic to motor neurons through genera-
tion of ROS. Focal Ig leakage may promote activation of microglia and astro-
cytes, contributing to nonautonomous cell death. Leakage of Ig that interacts
with motor neuron antigens may exert direct toxic effects on motor neurons.
VEGF promotes angiogenesis and protects neurons from hypoxic injury and
toxicity resulting from Hb and Ig leakage.of the immunological BBB. As discussed below, the immunolog-
ical BBB controls exchanges of immune cells and their media-
tors between blood and brain.
Leukocyte Entry into the CNS
Few leukocytes are normally present in the CNS. Most work on
the trafficking of leukocytes in the CNS came from studies using
disease or injury models. These studies revealed at least three
distinctive routes for leukocyte entry into the CNS: (1) from blood
to CSF across the choroid plexus; (2) from blood to subarachnoid
space; and (3) from blood to parenchymal perivascular space
(Ransohoff et al., 2003; Engelhardt and Ransohoff, 2005; Man
et al., 2007). The blood-CSF route has physiological significance
since the CSF of healthy individuals contains 3,000 leukocytes
per ml. In the CSF, T cells represent 80% of leukocytes. In the
second route, leukocytes extravasate across postcapillary ve-
nules at the pial surface of the brain into the subarachnoid space,
and from there enter the Virchow-Robin perivascular spaces. The
perivascular spaces are considered probable sites of lympho-
cytic interaction with antigen-presenting cells, and are important
for immune surveillance. The activated T cell blasts can also
extravasate across the postcapillary venules into the brain paren-
chyma (third route).
BBB Transport
The BBB mechanisms critically regulate immune responses of
the CNS in conditions such as MS and experimental models of
MS, such as EAE. During the course of EAE, autoaggressive
CD4+ T lymphocytes are activated outside the CNS. They accu-
mulate in the brain and CSF by crossing the BBB and the blood-
CSF barrier (Ransohoff et al., 2003; Engelhardt and Ransohoff,
2005; Man et al., 2007). It has been proposed that CSF central-
memory CD4+ T lymphocytes carry out routine immunosurveil-
lance of the CNS by searching within the CSF-filled subarachnoid
spaces for recall antigens presented by either subarachnoid
space macrophages or pericytes.
In the EAE models, transport of different subsets of cytotoxic T
lymphocytes from blood to brain is critical for lymphocytic infil-
tration of the CNS, which in turn results in neuronal killing. It is be-
lieved that Th17 lymphocytes, which secrete interleukin-17, may
play an important role in neuronal killing (Stockinger and Veld-
hoen, 2007). But whether Th17 lymphocytes are activated from
pre-Th17 subsets of T cells in peripheral organs and transported
across the BBB, or whether Th1, Th0, or other pre-Th17 lympho-
cytes initially penetrate the BBB followed by maturation into
Th17 cells in the CNS locally, is still a matter of debate. Recent
studies suggested that Th17 cells can penetrate the BBB (Kebir
et al., 2007). The BBB mechanisms that mediate transport of
different subsets of T cells into the CNS represent potentially
important therapeutic targets.
Figure 8 shows factors determining the transport of leukocytes
across the cerebral endothelium in inflamed postcapillary ve-
nules on the pial surface. Leukocyte extravasation takes place
in different steps that include rolling, activation, adhesion, and
transmigration (Engelhardt and Ransohoff, 2005; Man et al.,
2007). In a simplified scenario, the interaction of selectins and
their ligands during the tethering/rolling phase, chemokines
and G-protein coupled receptors during the activation phase, in-
tegrins and endothelial cell adhesion molecules (CAMs) during
the adhesion phase, and chemokines, chemokine receptors,Neuron 57, January 24, 2008 ª2008 Elsevier Inc. 193
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entry of recently activated or chronic memory leukocytes into dif-
ferent CNS sites. The later stages of extravasation require inter-
actions between G protein-coupled receptor on leukocytes (e.g.,
chemokine receptors) and an appropriate ligand (e.g., chemo-
kines). Chemokines mediate the activation of integrins on leuko-
cytes to achieve adhesion, i.e., a state of high-affinity binding
with CAMs on the endothelium. A second set of signals through
chemokines on the luminal and abluminal side of the BBB and G
protein-coupled receptors on endothelium leads to cytoskeletal
reorganization, which permits transmigration of leukocytes
across the BBB. A number of TJ molecules participate, including
JAM-A and ESAM. Leukocytes can extravasate by paracellular
or transcellular route across the BBB.
New therapies based on blocking transport of central memory
T cells, effector memory T cells, and activated monocytes with
Natalizumab (therapeutic neutralizing monoclonal antibody to
a4 integrin) across the BBB have been reported (Ransohoff,
Figure 8. Schematic of the BBB Involvement in the Pathogenesis of
Multiple Sclerosis, or MS
Leukocyte extravasation across the activated endothelium of the pericapillary
venules on the pial surface of the brain involves four stages: tethering and roll-
ing, activation, adhesion, and transmigration (or diapedesis). Leukocytes
tether to endothelial cells through binding of selectins to their carbohydrate
ligands. A simplified schematic on the bottom illustrates selectins only on
endothelium, although selectins can also be expressed by leukocytes. Rolling
requires interaction between chemokines expressed at the luminal membrane
of the BBB with G protein-coupled chemokine receptors on leukocytes. Inter-
action between chemokine receptors on leukocytes with endothelial luminal
chemokines initiates signals that lead to clustering and conformational
changes of the cell surface integrins on leukocytes. Adhesion requires trans-
formation of integrins on leukocytes into a form that can bind to their ligands,
typically CAMs on the luminal side of the BBB, with high affinity. This high-af-
finity/high-avidity reaction between integrins and adhesion molecules medi-
ates leukocyte arrest and adhesion. Transmigration happens after the arrest
phase by paracellular transport across the endothelial junctions, transcellularly
across the endothelial cells, or both. Leukocytes locomote on the endothelial
surface until they identify the interendothelial junctions. Next, they extend their
protrusions through the interendothelial junction and search for chemokines
expressed on the abluminal side of the BBB. Chemokine-chemokine receptor
interactions guide the extravasation of leukocytes. These interactions mediate
the cytoskeletal changes in leukocytes, resulting in a change of their shape to
allow transmigration. Transmigration follows chemotactic gradients. Extrava-
sating cells cluster in the perivascular space, between the endothelial base-
ment membrane and the basement membrane of the glia limitans, awaiting
transfer into the brain extracellular space. This requires an additional transport
step across the glia limitans mediated by matrix metalloproteinases (MMPs).194 Neuron 57, January 24, 2008 ª2008 Elsevier Inc.2007). T cells express a4b1 integrins on the cell surface, and their
transport across the BBB into the CSF and into the MS lesions
was blocked by Natalizumab. Natalizumab binds and inactivates
the integrin molecule on leukocytes. Its therapeutic effects
include dramatic reductions of the BBB breakdown in recipients
with active MS and lowering the counts of CSF leukocytes
by over 60%, compared with subjects with no inflammatory
diseases.
AIDS Dementia
The AIDS Dementia Complex (ADC) is the most common and
clinically important CNS complication of late HIV-1 infection. It
is a source of great morbidity and, when severe, is associated
with limited survival. While its pathogenesis remains unclear,
ADC is generally believed to be caused by HIV-1 itself, rather
than by another opportunistic infection.
BBB-regulated cellular trafficking is critical for the develop-
ment of CNS pathology caused by HIV-1, as well as other neuro-
inflammatory conditions including meningitis and encephalitis.
HIV-1 infiltrates the CNS largely via infected monocytes and
macrophages. According to the current concept, HIV-1 infiltra-
tion is mediated by its envelope glycoprotein, gp120, which ac-
tivates protein kinase C isoforms in BEC to alter the BBB perme-
ability and allow monocyte migration (Kanmogne et al., 2007).
The involvement of MMPs during HIV-1 infiltration, as well as in
other disorders of the CNS such as MS and cerebral ischemia,
as discussed above, and migraine and brain tumors, is well
established. Transport of peripheral monocytes carrying the
HIV-1 virus across the BBB into the CNS precedes development
of AIDS dementia. Better understanding of the BBB molecular
mechanisms is not only important for understanding the patho-
genesis of the disease, but will likely lead to the discovery of
new therapeutic targets and agents to control ADC.
Future Challenges
As discussed in earlier sections, a growing body of evidence
suggests that neurovascular mechanisms and disruption of the
BBB may precede, accelerate, or contribute to chronic disease
processes in neurodegenerative disorders of the adult and aging
nervous system. The examples include, but are not limited to (1)
faulty BBB clearance of potential brain toxins in AD and PD; (2)
inefficient clearance of excitotoxins across the BBB after an is-
chemic insult or traumatic brain injury; (3) increased transport
of leukocytes across the activated BBB in MS, AIDS dementia,
and AD, and during neuroinflammatory CNS responses, and (4)
BBB breakdown in ALS, AD, epilepsy and MS.
Numerous challenges remain. At the BBB level, a number of
carrier-mediated transporters, such as those for neuropeptides,
choline, thyroid hormones, vitamins, and nucleobases, remain to
be cloned. Many active efflux transporters and receptor-medi-
ated transporters have not been cloned. The transport mecha-
nisms that regulate levels of different proteinacious aggregates
inside the brain, such Ab, need to be refined in greater detail,
and for others, e.g., a-synucleins, huntingtin, SOD1, they remain
to be discovered. The role of the TJ proteins in the pathogenesis
of neurodegenerative disorders remains to be explored as well.
Developing new genomic and proteomic discovery platforms
will enable us to identify new BBB transporters and junctional
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and the junctional interendothelial proteins to look for genetic
susceptibility to neurodegenerative disorders is an important
priority. If BBB transporters, receptors, and interendothelial pro-
teins contribute to susceptibility or progression of neurodegener-
ation, then manipulation of such transport systems and barrier
function may offer neuroprotective and treatment strategies.
New BBB transporters and junctional proteins could also be
potentially utilized as portals of entry for cerebral drug targeting
systems.
The transport mechanisms of the BBB have not been fully
characterized in humans. Better knowledge of human BBB
transport systems is essential for translating findings from animal
disease models to humans. Progress in neuroimaging should
allow us to measure in vivo barrier activity and function of key hu-
man BBB transporters. Construction of a human BBB molecular
atlas could be a major advancement toward understanding the
role of the BBB in health, disease, and drug delivery to the brain.
Challenges for the future include understanding the crosstalk
between nonneuronal cell types (e.g., glia and microglia), cells
of the vessel wall (e.g., endothelium and pericytes), and neurons
(with each other), and possibly between neurons and peripheral
hematopoetic cells and vascular niches and neurogenic loci in
the brain. Identifying how these cells respond to, process, or
synthesize different receptors, and identifying the ligands that
mediate their interactions, is critical to understanding how these
same cells regulate the neuronal milieu.
Experiments that selectively examine leukocyte trafficking into
meningeal, parenchymal, and ventricular sites should further
clarify immunological specialization of the CNS. Investigation
of the molecular mechanisms of transmigration of different leu-
kocyte subpopulations across the BBB is critical for developing
specific strategies to control the neuroinflammatory response.
An overall goal of future research in drug targeting is to expand
the CNS drug space from lipid-soluble small molecules to the
much larger space of neurotherapeutics that includes molecules
that do not normally cross the BBB. For example, future studies
should continue to explore the translational potential of ap-
proaches that are currently in different stages of preclinical
development, including (1) the molecular Trojan horses that
use either monoclonal antibodies against the BBB receptors
(e.g., insulin and transferrin) to ferry across the BBB an attached
drug, protein, antisense agent, or nonviral plasmid DNA, or pegy-
lated immunoliposomes to deliver short hairpin RNA to control
neurotransmitter levels or growth factor activities; (2) delivery
of pharmaceuticals encapsulated into nanoparticles conjugated
to ligands for BBB receptors (such as LDL apoproteins) to carry
drugs across the BBB via the BBB LDL receptor; and (3) delivery
via the BBB receptors that are particularly expressed in the dis-
ease state, as for example RAGE in AD, diabetic vasculopathy,
or stroke.
With the present exciting developments and new future direc-
tions, continued BBB research will change the face of neurome-
dicine in the decades to come, with hundreds of millions of
people worldwide predicted to benefit from our better under-
standing of the role of the BBB in neurodegenerative disorders
and its potential role in new diagnostic and therapeutic
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